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Abstract
Influenza A has 8 genes encoding only 11 proteins and as such requires the use of a
large number of host proteins in order to complete its lifecycle. Recently, through
the use of whole genome RNAi screening, α coatamer protein (COPA) has been
shown to be an important host factor in the life cycle of a number of viruses
including low pathogenic influenza A H1N1. Here we demonstrate that COPA is
also important for the replication of highly pathogenic avian influenza
A/chicken/Vietnam/008/2004 H5N1 in vitro. H5N1 growth was shown to be
inhibited in HeLa cells treated with short interfering (siRNAs) targeting down-
regulation of COPA via the RNAi pathway.  The role of COPA in the interaction of
host cells with H5N1 was demonstrated using a number of assays, including
TCID50, and confocal microscopy. COPA siRNAs were shown to disrupt the Golgi
bodies in transfected cells, resulting in virus inhibition in cells infected with H5N1
48h post transfection, suggesting a vital role for the Golgi during influenza
infection. Similarly, the expression of a number of cytokines were measured in
HeLa cells using a human α,β  interferon response qPCR array following infection
with H5N1. A number of genes were disregulated in response to infection with
H5N1 with the largest response seen in the expression of SLC35A1, a solute carrier
family 35 (CMP-sialic acid transporter), member A1 which encodes a gene found in
the membrane of the Golgi apparatus. These results suggest that COPA plays a vital
role in the growth of A/chicken/Vietnam/008/2004 H5N1 and that this role is
related to the interaction of COPA with the Golgi. In order to visualise the
effectiveness of the COPA silencing on inhibiting the growth of virus in vitro, work
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was done to develop a GFP- expressing H1N1 virus using an 8-plasmid reverse
genetics system to rescue a virus which comprised a NS gene that incorporated a
GFP gene segment. Although a functional NS-GFP plasmid was able to be
generated, live GFP-expressing virus was not able to be rescued and as an
alternative antibody staining was used to visualise virus.
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Viruses are obligate pathogens which vary in their host preference and their ability
to cause disease (Campbell et al., 2006). Many viruses are capable of transmission
between species, in particular transmission from animals to humans. Viruses that
can be transmitted from animals to humans are classified as zoonotic viruses.
Examples of zoonotic viruses which have emerged recently capturing public
attention are the 2009 Swine origin H1N1 virus and highly pathogenic avian
influenza virus (H5N1). These zoonotic viruses pose a significant risk as a human
pandemic. For example, swine flu (pandemic swine-origin H1N1/09) emerged in
early 2009 in Mexico, and by the 18th of April 2010, it had rapidly spread to more
than 214 countries across the globe, becoming the dominant seasonal circulating
influenza for 2010 (Taubenberger and Morens 2010) Fortunately, this virus has a
relatively low mortality rate of 2%. More concerning is H5N1, with an alarmingly
high mortality rate of 60%. The potential dissemination of H5N1 if it were to adapt
to become transmissible from human to human through antigenic shift, a process by
which two or more differing strains of a virus, or different viruses combine to form
a new virus subtype containing a mixture of surface antigens from the original
strains, is a matter of great concern.
Since virus infection causes a significant impact on human and animal
health worldwide, there has been constant research towards the development of
antiviral therapeutics. Current approaches to treat and prevent viral infections
include the use of vaccines and antiviral drugs. The efficacy of these vaccines and
antiviral drugs can be limited, particularly where influenza virus is involved.
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Existing antiviral drugs are not sufficiently effective against highly pathogenic
viruses and the production of new vaccines is required in order to combat influenza
viruses due to their ability to mutate (As discussed in section 1.4). A vaccine works
by priming the immune system to recognize the surface antigens on a virus. The
constant mutation of viral genomes leads to the production of new forms of these
surface antigens. If these changes are significant, the virus will not be recognized by
the immune system and the virus can evade the adaptive immunity which is
provided by the vaccine.
In addition, in the event of a H5N1 pandemic, it is likely that millions of
people would become infected before the vaccine could be developed and
distributed; a process which takes approximately 6 months (Steel 2011). Thus, there
is an urgent need for new therapeutics. However, to develop new therapeutics we
must identify new targets within either the virus, or as an emerging theme, the host.
One possible therapeutic approach is the use of RNA interference (RNAi) to silence
these host factors and such an approach will be discussed in detail in section 1.10.
RNAi therapeutics have potential not only as anti-H5N1 therapeutics but may also
be effective against other viruses such as H1N1.
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Influenza A viruses are small (80 to 120 nm in diameter) segmented, negative-
strand RNA viruses belonging to the Orthomyxoviridae family (Webster, Bean et al.
1992). Influenza A viruses are classified based on the type of their two surface
proteins, haemagglutinin (HA) and neuraminidase (NA). There are 16 HA subtypes
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and 9 NA subtypes. For example, H5N1 has a HA type 5 protein and a NA type 1
protein (http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm). Avian influenza A
virus is classified as either low pathogenic (LPAI) or highly pathogenic (HPAI)
based on their specific molecular genetic and pathogenesis criteria that require
specific testing. Influenza A subtypes H5 and H7 that are typically associated with
HPAI include H5N1, H7N7 and H7N3 (http://www.cdc.gov/flu/avian/gen-info/flu-
viruses.htm).
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Influenza A viruses consist of 8 gene segments (Figure 1.1) encoding 11 proteins
encapsulated within a lipid bilayer (Figure 2b) (Webster, Bean et al. 1992, Rossman
and Lamb 2010). This includes a haemagglutinin gene (HA), which encodes a
surface haemagglutinin glycoprotein that is essential for virus attachment to host
cell receptors and also for the fusion of the virion envelope to the host cell (Figure
2c) (Taubenberger and Morens 2010 2010). It also includes a neuraminidase gene
(NA), which encodes a surface neuraminidase glycoprotein required for the release
of the virus from host cells (Figure 2c). This neuraminidase cleaves terminal sialic
acid from the glycoproteins, allowing the release of the virus particles from the cell
and hence the release and spread of viral progeny. Haemaglutinin and
neuraminidase are both embedded within the lipid bilayer of the virion (Webster,
Bean et al. 1992).
Each virion also contains a nucleoprotein gene (NP) segment which encodes
nucleoprotein that has a structural role, as well as three segments, polymerase basic
2 (PB2), Polymerase basic 1 (PB1), and PA, each of which each encode RNA
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polymerase proteins. PB2 protein plays a role during the initiation of the
transcription of viral mRNA, PB1 proteins aids in the elongation of viral mRNA
and template RNA, whilst the role of PA protein in this complex is thought to be
involved in viral genome replication by inducing the proteolysis of both viral and
host proteins (Kawaguchi, Naito et al. 2005). Collectively, these 3 polymerases and
the nucleoproteins combine to form the viral nucleoprotein (vRNP) (Paragas, Talon
et al. 2001). Each virion also contains a matrix (M) segment which encodes M1
matrix protein and M2 protein. M1 protein acts to form a shell around the virion
nucleocapsids and is the most abundant protein within the virion, whilst M2 is an
integral membrane protein which has a proton-selective ion channel activity and is
also involved in virus assembly (Webster, Bean et al. 1992) ,(Rossman and Lamb
2010). In addition, the virion also contains the non-structural (NS) gene segment
encoding a multifunctional protein non-structural 1 (NS1), which is an interferon
agonist and NS2 (also known as NEP) proteins that are essential for nuclear export
of vRNPs (Maines, Szretter et al. 2008). The export of vRNPs from the nucleus to
viral assembly sites on the cellular plasma membrane is essential for the later stages
of viral replication (Heldt et al., 2012). Altogether these 8 segments combine to
create a complete virus, and the individual arrangements of these segments allow
for the different subtypes of influenza viruses present.
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Figure 1.1 Influenza A
a. Influenza virus contains the surface proteins, haemagglutinin and neuraminidase.
b. The virus in encapsulated by a lipid bilayer. c. Influenza virus contains 8 gene
segments.  (Figure adapted from Maines et al., 2008, Guan et al., 2009) (Maines,
Szretter et al. 2008) (Chan, Cheung et al. 2005)
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Influenza, like all viruses, lacks the essential proteins and machinery needed for
replication and thus requires a host cell to complete their life cycle (Webster, Bean
et al. 1992). Although we now have a good understanding of the role of each of the
8 genes in the replication of the viral genome, in comparison our understanding of
the interactions of the 11 proteins these genes encode with the hundreds of host
cellular factors is limited. Identifying these interactions will increase our knowledge
of the virus lifecycle within the host and provide us with potential antiviral targets.
For influenza, the synthesis of viral RNA occurs within the nucleus of the
host cell (Webster, Bean et al. 1992). Here the virus interacts with the host cell
nucleus in order to replicate its genome and produce new virus particles (Amorim
and Digard 2006). These interactions can be looked at as “hijacking”, whereby the
usual cellular function is being inhibited in order to allow the virus to make use of
the machinery to replicate its genome (Amorim and Digard 2006) The replication of
the virus involves not only the interactions within the nucleus of the host cell, but
also interactions with cell components. These include interactions with the cell
membrane during internalization and virus release from the cell interactions with
cellular proteins and organelles within the cytoplasm as well as general association
with many cellular pathways (Webster, Bean et al. 1992). A complete viral lifecycle
includes viral fusion to the cell membrane, virus entry, uncoating, nuclear import,
transcription and translation, nuclear export, virus assembly, trafficking to the cell
surface and budding and release from the cell (Watanabe, Watanabe et al. 2010).
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Identifying host factors involved in virus lifecycles is particularly important when
we consider the rate with which influenza viruses mutate, which can render current
therapeutics ineffectual.
Influenza viruses evolve very rapidly. This rapid evolution is a result of their RNA
polymerase that lacks a proofreading mechanism for the accurate replication of
genetic material (Taubenberger and Morens 2010). There are a number of
mechanisms by which viruses can evolve, including reassortment, also known as
antigenic shift, a process by which a virus obtains a gene segment of a new subtype
via genetic reassortment with another influenza virus. This process occurs when
two or more viruses exchange genetic material after infection of the same cell
(Taubenberger and Morens 2010). Other mechanisms include point mutations, also
known as antigenic drift, which account for approximately 1 × 103 to 8 × 103 base
substitutions per year (Taubenberger and Morens 2010) and RNA recombination
(Webster, Bean et al. 1992). Many of these mutations appear as changes in the
amino acids present in the surface glycoproteins which are an important factor for
viral recognition by host, and can produce advantages for the virus that allow them
to evade pre-existing immunity to viruses. Others occur within one of the 8 gene
segments themselves (Webster, Bean et al. 1992). Antigenic drift occurs due to the
increased immune pressure seen on these genes compared to other viral genes.
(Taubenberger and Morens 2010).
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It is the differences in these gene segments due to mutations which allow for the
many different potential Influenza A strains. There are sixteen HA and nine NA
subtypes which may be arranged to form a number of different strains, some of
which are only mildly pathogenic whilst others have the ability to infect and
overwhelm a variety of species (Loeffelholz 2010). In poultry, these viruses are
described as either low pathogenic or high pathogenic influenza viruses respectively
and both have had a significant impact on animal and human health.
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Influenza A viruses are present across the globe and have the ability to infect a wide
range of host species including wild birds, domestic birds, pigs, horses and humans
(Taubenberger and Morens 2010). The ability of influenza virus to infect such a
large number of species and the ability of the virus to be transmitted between these
hosts, allows for the emergence of novel influenza viruses due to reassortment,
which ensures the continued propagation of the virus. Only a portion of these
viruses can infect humans. Each year influenza viruses are responsible for the
infection of approximately three to five million people resulting in around 250,000
to 500,000 deaths across the globe
(http://www.who.int/mediacentre/factsheets/fs211/en/index.html). Deaths resulting
from influenza virus infection primarily involve the very young, the elderly, or the
immune suppressed, and death may be a direct result of influenza infection, or due
to complications such as bacterial infections or pneumonia (Poland, Jacobson et al.
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2007). Due to the constant mutations occurring, new virus strains emerge each year.
The emergence of viruses to which no previous immunity has been developed,
however, can result in pandemic events.
There have been a number of Influenza pandemics in recorded history, with
some of the most significant having occurred over the last 500 years (Taubenberger
and Morens 2010). There have been around 14 pandemics recorded since 1500 AD
(Guan, Vijaykrishna et al. 2010). There have been a number of major pandemic
events in recent history, three of significance within the 20th century in 1918, 1957,
and 1968, each of which caused a considerable mortality (Guan, Vijaykrishna et al.
2010). More recently in 2009, another influenza pandemic involving a swine origin
H1N1 virus occurred.
The Spanish influenza pandemic of 1918-1919, which as undoubtedly the
most severe pandemic on record, was caused by an H1N1 virus generated by the
reassortment of new avian influenza viruses with swine and human influenza strains
already in circulation (Guan, Vijaykrishna et al. 2010). It was not until the 1930’s
that influenza viruses were first isolated, therefore characterization of the 1918
Spanish influenza virus did not begin until 1995, when viral fragments extracted
from the preserved lung tissue of patients infected with the 1918 flu were amplified
using PCR to allow sequencing of the virus (Taubenberger, Reid et al. 2005).
Spanish influenza spread across the globe causing up to an estimated 20 to 50
million deaths worldwide (Guan, Vijaykrishna et al. 2010). On the other hand, the
Asian influenza pandemic of 1957-1958 was caused by a H2N2 virus, which
emerged due to reassortment between a previously circulating human H1N1 strain
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with an avian influenza virus that had been circulating throughout Europe. This
pandemic was responsible for approximately 500,000 deaths (Kilbourne 2006),
(Guan, Vijaykrishna et al. 2010). The next major influenza pandemic, the Hong
Kong influenza pandemic of 1968-1969, was the result of an H3N2 virus
(Taubenberger and Morens 2010). This virus developed due to the incorporation of
PB1 and novel HA/NA segments into a virus that has been already circulating in
humans (Guan, Vijaykrishna et al. 2010). During the time of its circulation it is
estimated to have caused approximately 2,000,000 deaths (Guan, Vijaykrishna et al.
2010).
The most recent influenza pandemic is the circulating 2009 H1N1 influenza strain.
This strain is a result of reassortment of genes between H3N2 and H1N2 triple
reassortant viruses first isolated in pigs in North America in 1998, along with the
inclusion of N and M genes from a H1N1 avian-like swine influenza strain
originally isolated in pigs in Europe in 1979 (Guan, Vijaykrishna et al. 2010). This
virus was first identified in Mexico in March 2009 and has since spread globally
(http://www.who.int/csr/don/2010_03_19/en/index.html). According to the World
Health Organisation (WHO), as of the 19th of March 2010, it had infected millions
of people with 16,813 documented deaths
(http://www.who.int/csr/disease/swineflu/en/).
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Highly pathogenic avian influenza A virus (H5N1) is an influenza virus created
through the reassortment of avian and human strains of influenza to produce a
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highly pathogenic strain (Chan, Cheung et al. 2005). Highly pathogenic Avian
Influenza is defined by the World Health Organisation as any Influenza Virus of the
H5 or H7 subtype or any avian influenza virus with either an intravenous
pathogenicity index (IVPI) greater than 1.2 or a mortality rate of 75% in poultry
(http://www.who.int/influenza/human_animal_interface/en/).
H5N1 affects many animal species including, poultry, ducks, and humans. It
emerged first in Guangdong Province in Southern China in 1996, where it was first
identified to have infected geese, and then in Hong Kong less than a year later
where it was first reported to be transmitted from infected poultry to humans
(Peiris, de Jong et al. 2007). There were 18 human cases in this instance resulting in
6 deaths (Taubenberger and Morens 2010). Following this, the virus circulated
throughout China, finally causing wide spread infection in poultry in 2003
throughout 60 countries over three continents (Taubenberger and Morens 2010).
According to the World Health Organisation, as of the 5th of April 2012, there have
been 600 documented human cases resulting in 353 deaths, a mortality rate of
around 60 %. The average age of infected patients is 18 years of age, with cases
being reported in people from 3 months of age to 75 years (Peiris, de Jong et al.
2007). H5N1 deaths are primarily due to respiratory distress caused by the
development of primary viral pneumonia in infected patients along with multiple
organ failure that may be associated with the increased cytokine response observed
during H5N1 infection (Chan, Cheung et al. 2005). This virus is also responsible for
millions of avian deaths including the 140 million birds which have been culled as a
measure to prevent further spread of disease, and for deaths in many other
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mammalian species all of which contribute a large economic impact (Taubenberger
and Morens 2010). The cost to the poultry industry alone is estimated to be around
10 billion US dollars {Esen and Ogus. 2006}.  This is particularly due to the large
scale farming practices employed in the poultry industry.
The transmission of H5N1 to human is through contact with infected poultry and
ducks. Due to the remote locations and inadequate medical care available in many
areas of Asia, particularly in farming regions, it is likely that the actual number of
human cases is much higher than records indicate due to unreported or
unrecognised cases. As yet, human to human transmission has not been
documented, perhaps because it is not yet adapted to efficient human to human
transmission (Peiris, de Jong et al. 2007), however, it remains a constant threat due
to the ability of influenza viruses to undergo change through reassortment and
mutation. If this virus gains the ability to be transmitted human to human, it is likely
to present a human pandemic threat.
Recently, a paper was published in Nature detailing the experimental adaption of an
influenza H5 HA virus in order to confer respiratory droplet transmission to a
reassortant H5 HA/H1N1 virus in ferrets (Imai, Watanabe et al. 2012). This
experiment involved assessing the molecular changes in HA that would allow a H5
influenza virus to become transmissible among mammals. They were able to
identify a reassortant H5 H/H1N1 virus which included a HA gene from a H5
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which had four mutations along with the seven additional genes that comprise an
influenza A virus which were taken from a H1N1 virus that was capable of
transmission in a ferret model. This virus recognised human receptors and was able
to cause disease in ferrets which resulted in lung lesions and weight loss although
was not highly pathogenic and did not cause mortality. This virus, whilst not highly
pathogenic, emphasises the real potential for this virus to become a pandemic threat
if it were to naturally gain mutations that allow human to human transmission and
gives further weight to the need for more research into antiviral therapeutics against
this virus (Imai, Watanabe et al. 2012).
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The first therapeutic approach generally considered for protection against influenza
infection is the use of vaccines. There are two types of vaccine; live attenuated
influenza vaccine (LAIV) and trivalent inactivated vaccine (TIV) (Nichol and
Treanor 2006). TIV contains enriched haemagglutinin protein whilst LAIV contains
a weakened version of the virus (Nichol and Treanor 2006). Each year a vaccine is
produced to protect against the current seasonal circulating Influenza virus and is
designed to protect against the predicted antigenic variants of influenza A (H3N2),
A (H1N1), and B viruses (Nichol and Treanor 2006)
In light of the potential pandemic risk, there has been a significant amount
of work on the production of vaccines against H5N1 in recent years. This work has
included the production of experimental live attenuated vaccines which were
developed using reverse genetics to introduce attenuating mutations into the
influenza virus genome and also the production of alternative vaccine strategies that
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do not rely on the use of live attenuated virus such as virus-like particles and DNA-
based vaccines (Steel). The live attenuated vaccines include those that have been
attenuated through temperature sensitive mutation, modulation of the interferon
antagonist protein or by disruption of the M2 protein (Steel).
So far have all of these vaccines have been able to show protection in
animal models of influenza infection to varying degrees (Steel). However, gains in
vaccine efficacy are required to produce a commercially available vaccine that will
successfully lower the mortality and morbidity which would be associated with
infection with a highly pathogenic avian influenza strain (Steel).
Whilst vaccination is still considered the paramount form of protection
against seasonal and pandemic influenza viruses, it should be noted that it can take
around 6 months for a vaccine to be developed once a strain has been identified
using current manufacturing techniques (Steel). In the event of a pandemic
involving highly pathogenic avian influenza H5N1 it is likely that a vaccine will not
be produced fast enough and, therefore, it is important to consider other antiviral
options (Steel).
	
#8+':3+4:5,4,2;+4@';9/4-'4:/</8'2*8;-9
Antiviral drugs which act specifically against influenza viruses comprise two major
classes, the adamantines and the NA inhibitors. The adamantines, which include
amantadine and rimantadine, are inhibitors of ion channel activities and the M2
membrane protein which are responsible for the acidification of the interior of the
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virus particle. This acidification is essential for the protein-protein dissociation that
is required for the proper uncoating of the virus, a process necessary before the
virus material can replicate (Pinto and Lamb 2007). The second class, the
neuraminidase (NA) inhibitors, includes oseltamivir and zanamivir (Peiris, de Jong
et al. 2007). These inhibitors block NA, the influenza surface glycoprotein which
enables the release of newly formed virions from infected cells (Harrod, Emery et
al. 2006). Whilst many studies have reported the effectiveness of these antiviral
drugs against a broad range of influenza viruses, the results are quite varied. In
Hong Kong during the 1997 H5N1 outbreak, in a period between May 15 and
December 22, 8 patients admitted with signs of H5N1 infection, were administered
amantadine on the third day of their admission. Of these 8 patients, 4 deaths were
recorded, 2 complete recoveries were recorded and two patients recovered with
complications that required further treatment including steroid treatment and the
short term use of a ventilator (Wong and Yuen 2006). The results of this study,
however, were not able to provide conclusions regarding the clinical efficacy for the
treatment of H5N1 (Wong and Yuen 2006).  Moreover, due to changes in the virus,
specifically amino acid replacements in the M2 segment, the H5N1 virus currently
circulating has begun to demonstrate amantadine resistance. For this reason, and
due to resistance which has developed in other strains such as recent endemic H3N2
strains, amantadine is no longer considered an effective treatment option against
human seasonal influenza or against H5N1 (Peiris, de Jong et al. 2007). More
promising as a treatment option against H5N1 are the NA inhibitors oseltamivir and
zanamivir to which some efficacy against H5N1 viruses isolated from patients has
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been shown in vitro (Peiris, de Jong et al. 2007). Recently, however, oseltamivir
drug resistance rates of up to 18% have been observed in children infected with
H5N1 (Peiris, de Jong et al. 2007). This has created some doubt against the
affectivity of this drug, though it is not yet apparent whether this is due to a lack of
prior immunity in the children that can allow for a higher viral replication rate
(Peiris, de Jong et al. 2007). The development of drug resistance forces us to
continue to look for new therapeutic options. One such option is the possibility of
targeting the host rather than the virus itself.
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Understanding the host pathways and cellular components manipulated and used
during virus replication allows us to better understand the infection process. This
knowledge allows for the potential development of new therapeutics against viruses
such as influenza A virus for which current therapeutics alone are not adequate. A
number of high throughput whole genome siRNA screens using methodologies
outlined in section 1.8.2 have been performed in recent years in order to identify
these host factors. Of the hundreds of genes identified as important for the many
stages of the virus lifecycle, there are a number of common host factors that have
been identified by these screens. Table 1.1 summarises a selection of genes
identified in common between these studies, which involve not only (low
pathogenic H1N1) influenza virus, but other viruses such as HIV, Hepatitis C, West
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Nile Virus, and Dengue Virus (Brass, Dykxhoorn et al. 2008, Krishnan et al., 2008,
Li et al., 2009, Tai et al., 2009).
Of particular note during the first stage of the viral lifecycle, involving the
fusion with the host cell, endocytosis and uncoating of the virus, pathways such as
the clathrin-dependant endocytosis pathway, as well as coatamer protein (COPI)
vesicle dependent vesicular transport and the ras-related protein 10 (RAB10) gene
are involved. The next major stage of the viral lifecycle, that being the transport of
the viral nucleoprotein into the host nucleus, again makes use of a large number of
host factors, but of particular importance are the active import machinery of the
host cell nuclear pore complex (NPC) and the importin subunits. Genes identified as
important in the next stage of the virus lifecycle, the transcription and translation of
the viral genome, include BAT1, Tat-SF1, and of particular importance the heat
shock protein (Hsp) 90. Genes and pathways recognized by these screens as
important for the transport of the vRNP from the nucleus to the cytoplasm include
heat shock cognate (Hsc) 70 and the MAP kinase cascade. Lastly, in the final stage
of the virus lifecycle, the assembly and budding of the virus, proteins such as those
that comprise the COPI complex again are identified as an important if not essential
host component (Watanabe, Watanabe et al. 2010). The specific role of a number of
these host proteins in the replication pathways are fully defined, however
information on the role of others such as alpha coatamer protein (COPA) are
lacking.
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Table 1.1 Summary of common host genes identified by high throughput whole
genome siRNA screens involving virus.
Virus Gene Function Publication
Influenza A
(H1N1), Dengue
Virus, West Nile
Virus
SLC35A1 Sialic-acid
transporter
(Karlas, Machuy
et al. 2010)
(Konig, Stertz et
al. 2010) (Li,
Brass et al. 2009)
(Mehle and
Doudna 2010)
Influenza A
(H1N1), Dengue
Virus, West Nile
Virus, Hepatitis C
COPA Vesicular transport
Complex
(Karlas, Machuy
et al. 2010)
(Konig, Stertz et
al. 2010) (Li,
Brass et al. 2009)
(Mehle and
Doudna 2010)
Influenza A
(H1N1), Dengue
Virus, West Nile
Virus
RAB10 Regulates
intracellular vesicle
trafficking
(Karlas, Machuy
et al. 2010)
(Konig, Stertz et
al. 2010) (Li,
Brass et al. 2009)
(Mehle and
Doudna 2010)
Influenza A
(H1N1), Dengue
IFITM Interferon-inducible
transmembrane
(Brass, Huang et
al. 2009) (Mehle
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Virus, West Nile
Virus
protein and Doudna
2010)
HIV MED28 Mediator Complex
component
(Brass,
Dykxhoorn et al.
2008) (Zhou, Xu
et al. 2008)
HIV MED4 Mediator Complex
component
(Brass,
Dykxhoorn et al.
2008) (Zhou, Xu
et al. 2008)
Figure adapted from Brass et al., 2008, Konig et al 2008, Konig et al., 2009, Karlas
et al., 2010, Mehle et al., 2010, Krishnan et al., 2008, Li et al., 2009, and Tai et al.,
2009, and Zhou et al., 2008.
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Studying the host response to influenza A infection will provide even more insight
into the host genes which are important for virus replication and therefore will
provide us with further candidates which may be useful to target with therapeutics.
Studying the host factors that play a role in the immune response to influenza
viruses is one way we can identify these candidates. There are two types of
immunity exhibited in response to infection with influenza, innate and adaptive
immunity.  Innate immunity includes they type I IFN responses as well as other
cytokine and chemokines that are secreted in response to infection, whilst adaptive
immunity includes the development of defenses such as CD4 helper T-cell (Th),
CD8 cytotoxic T-cell (Tc) and antibody responses (Summerfield and McCullough
2009).
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It has been hypothesised that the severity of the disease caused by highly
pathogenic Avian Influenza is due to the hypercytokinemia, or “cytokine storm”
exhibited during infection (Hagau, Slavcovici et al. 2010). A cytokine is an
extracellular signaling protein whose role is as a local mediator in communication
between cells (Alberts, Srivastava et al. 2010). In particular they activate
lymphocytes and other immune cells which fight the virus infection {Campbell et
al., 2006}. Typically, the response to influenza A infection is characterised by the
high level expression of cytokines such as  IL-6, IL-8, IL-9 and IL-17, which are
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known to mediate Th17 cell development, a type of T cell that mediates both host
defense and pathological inflammation (Peck and Mellins)
as well as the mediators of Th1 cells, TNFα, IL-15, 1L-12, and type II interferons
(Hagau, Slavcovici et al. 2010). There have however, been some recent studies
which put doubt towards this hypothesis, including a study by Salomon and
colleagues (Salomon, Hoffmann et al. 2007), which showed that inhibiting cytokine
production did not protect mice against a lethal H5N1 infection, and a study by
Deng and colleagues in 2008 (Deng, Lu et al. 2008) which measured the cytokine
expression in two adult H5N1 autopsies and a foetus obtained during the autopsy
(Salomon, Hoffmann et al. 2007 2008). This study showed that antigens of 10
cytokines and the mRNA of 8 of those cytokines that have been shown to be
increased in previous lethal H5N1 cases, were absent in pregnant female and the
foetus. Yet the male autopsy found that antigens of 7 cytokines and mRNA of 6
were present in high levels in the lungs. In addition, the levels of cytokines found in
the serum were found to be significantly higher that levels witnessed in previous
H5N1 infection cases. These inconsistencies would indicate that cytokine storm
alone may not be an adequate explanation for the severity of H5N1 infection (Deng,
Lu et al. 2008)}.
The cytokine response is also important when studying the response to
seasonal influenza strains. Recently, Lee and colleagues performed a study of
patients hospitalised with the 2009 swine origin A/H1N1 virus where they
examined the concentrations of cytokines and chemokines in plasma and peripheral
blood mononuclear cell (PBMCs). They found that in complicated cases of swine
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origin A/H1N1, or in cases where virus infection led to pneumonia, hyperactivation
of proinflammatory cytokines was evident but absent in milder cases, suggesting
that cytokine dysregulation may be important in the pathogenesis of swine origin
A/H1N1 infections(Lee, Wong et al. 2011). Identifying these cytokines is an
important step to understanding the role of cytokine host factors. Once we have
identified important candidates involved in the virus lifecycle or in the host
response to virus, we can then manipulate these candidates using tools such as
RNAi technology.
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RNA interference (RNAi) is a natural cellular pathway involving the silencing, or
blocking of expression of genes by small interfering RNAs (siRNAs) in a sequence
dependent manner, that is the silencing of those genes who share sequence identity
to the siRNA sequence (Fire, Xu et al. 1998 2002)}.  It evolved as a means of
controlling biological processes such as the control of endogenous gene expression,
silencing of transposable elements and repetitive genes, and as a defense against
virus attack (Aliyari and Ding 2009)}. Evidence of RNAi was first noted in plants
as early as 1923 by Wingard et al. in an experiment involving an immune response
in Tobacco plants to tobacco ringspot virus and further characterised as a natural
mechanism by which plants defend themselves against RNA viruses in experiments
using a variety of plant species including the model plant Arabidopsis thaliana
(Schlee, Hornung et al. 2006). The recognition of the RNAi pathway however, was
first published by Napoli et al in 1990. This was an unexpected discovery in an
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experiment aiming to over-express the pigment producing gene chalcone synthase
(CHS) in purple pigmented petunias in an attempt to increase the amount of
pigment produced. The result of this experiment however, was the production of
flowers with either no, or variegated colour. It was determined that the reason for
the suppression of pigment production was due to suppression of the anthocyanin
pathway via the silencing of both the homologous and the introduced gene {Napoli
et al., 1990}. RNAi was first characterised in animal cells in 1998 by Fire and
colleagues using the nematode Caenorhabditis elegans, in an experiment performed
to investigate the requirements for structure and delivery of interfering RNA
molecules (Fire, Xu et al. 1998). They were able to demonstrate that double
stranded RNAs (dsRNAs) caused more potent sequence-specific silencing than
single stranded RNAs (Fire, Xu et al. 1998). Evidence of RNA interference was
then shown in mammalian cells by Wianny and Zernicka-Goetz in 2000 using
mouse oocytes and early embryos, in an experiment using dsRNA to silence three
genes; maternally expressed c-mos in the oocyte, zygotically expressed E-cadherin,
and a GFP transgene in pre-implantation embryos. (Schlee, Hornung et al. 2006),
(Wianny and Zernicka-Goetz 2000). Whilst the RNAi mechanism was shown to be
conserved amongst mammalian cells in 2002 by Harborth and colleagues, the
natural anti-viral effects have not been shown (Harborth, Elbashir et al. 2001).
MiRNAs which are also involved in the RNAi pathway, are short ~22 nucleotide
non-coding RNA molecules that control gene expression via either translational
repression or mRNA degradation {Meister et al., 2007}. Each miRNA potentially
plays a role in modulating the expression of hundreds of genes and any inhibition
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may trigger larger effects downstream {Castonotto et al., 2009}. The RNAi
pathway (Figure 1.2) is dependent on the recognition of long double stranded RNA
(dsRNA) (Figure 1.2 a) by cytoplasmic sensors in a cell known as pathogen
recognition receptors (PRRs). PRRs are a broad class of receptors that are
associated with the innate immune response. They include recognition molecules
such as the Toll-like receptors, the RIG-I-like receptors, and the NOD-like
receptors. The role of PRRs in the innate immune response is the activation of
interferons and the transcription factor NF-κB, which leads to an inflammatory
antiviral immune response {Yokota et al., 2009}. The PRR Dicer recognises both
endogenous dsRNA and viral RNA and is a member of the RNAse III family
(Aliyari and Ding 2009). Its role in RNA interference is to process long dsRNAs
and pre micro RNAs (pre-miRNAs), the latter being small double stranded RNA
molecules approximately 9-12 bp long, into short dsRNAs (21-23nt) (Figure 1.2 b,
c) (Sakurai, Amarzguioui et al. 2010). It does this with the association of the co-
factor RNA-binding protein TRBP. The recognition of dsRNA by Dicer is also
responsible for stimulating anti-viral responses, including the induction of Type I
IFN (Karpala et al., 2005). Mammalian systems have only a single class of Dicer
proteins which processes both pre- miRNAs and long dsRNAs, as opposed to the
better studied system in Drosophila which contain two Dicer proteins; Dicer 1,
which is responsible for the processing of pre- miRNAs, and Dicer 2, which is
responsible for the processing of long dRNAs into siRNAs (Huntzinger and
Izaurralde). After processing by Dicer, the resulting siRNAs are introduced into the
RNA-induced silencing complex (RISC), a multiprotein complex that can be
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programmed to target any gene for silencing (Pratt and MacRae 2009). RISC
consists of Dicer, Argonaute 2 (AGO2), TRBP (HIV-1 TAR RNA binding protein)
and PACT, a protein which binds double-stranded RNA (Figure 1.2 d) (Gaglione
and Messere), 2010. Here the passenger strand is lost and the guide strand of the
siRNA is led to base pair with target messenger RNA (mRNA) that shares sequence
homology (Sakurai, Amarzguioui et al. 2011), (Pratt and MacRae 2009). This
process is catalysed by AGO2, which either cleaves the target mRNA or aids in the
binding and positioning the siRNA in the appropriate conformation as to allow
target recognition by associated proteins to cleave the target mRNA, which in turn
prevents translation (Figure 1 d) (Sakurai, Amarzguioui et al. 2011), (Pratt and
MacRae 2009).
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Figure 1.2: RNA interference pathway
a. Endogenous long dsRNA is present in the cell. b. Long dsRNA is cleaved by the
enzyme Dicer into siRNAs before being loaded into RISC. c. siRNAs are
approximately 19-21 bp long. d. The passenger strand of the siRNA is lost and the
guide strand binds in a sequence-dependent manner to messenger RNA (mRNA), in
a process catalysed by the argonaute protein component of RISC. e. Target mRNA
is then degraded. (Figure adapted from {Castonotto et al., 2009})
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In order to silence each gene or a subset of genes (i.e. within a pathway) within a
cell to explore gene function, siRNA libraries are utilised in screening approaches
(Chen, Du et al. 2007). Typically a siRNA library consists of multiple (up to 4)
siRNAs targeting each gene, which are pooled together to provide a cumulative
silencing effect, which greatly increases the efficacy of silencing compared to that
of the use of a single siRNA
(http://www.dharmacon.com/product/productlandingtemplate.aspx?id=193). A
siRNA library can be produced in one of three ways; by chemical synthesis,
through expression by plasmid or viral vectors, and by the enzymatic cleavage of
cDNA-derived long dsRNA by Dicer (Chen, Du et al. 2007). These siRNA libraries
are available for a number of organisms, including, H. sapiens, M. musculus, D.
melanogaster, C. elegans, and T. brucei and in theory, a library can be generated for
any organism whose genome has been sequenced and for which the silencing
machinery is present (Chen, Du et al. 2007). In terms of the human genome, a
whole genome siRNA screen generally consists of a library of over 80,000 siRNAs
which are designed to silence each of the approximately 18,500 human genes.
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Whole genome siRNA screens involve the use siRNA libraries to silence a large
number of individual genes, therefore allowing the function of each individual gene
within a genome to be determined through loss of function observations (Chen, Du
et al. 2007) (Figure 1.3). Typically screens are used to identify genes important to a
single specific cellular function or disease. Finding host genes that play a role
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during a virus infection is an example of one use of a whole genome screen (Chen,
Du et al. 2007). Following initial screening using a complete pooled library,
secondary screening is necessary to validate gene hits that have been identified in
the initial screen. This secondary screening confirms hits by eliminating those that
have been incorrectly identified due to errors such as false positive readings
(Harborth, Elbashir et al. 2001). To reduce the risk of including false positives in
the results as ‘hits’, multiple reagents targeting the same gene of interest are often
used and the results of multiple screens are often combined (Birmingham, Selfors et
al. 2009). Other concerns with high throughput screening include the
immunostimulatory effects of the RNA molecules used to silence the genes. These
molecules have the potential to stimulate a type I IFN response through their
interaction with Dicer as previously discussed (Karpala et al., 2005). This off-target
effect is taken into consideration when designing the siRNAs to be used in the
screen in order to minimise the potential for the induction of an immune response
(www.dharmacon.com).
There are currently only three research institutions in Australia equipped to
do whole genome RNAi screens; the Monash Institute for Medical Research,
Victorian Centre for Functional Genomics housed at the Peter MacCallum Cancer
Centre (East Melbourne, Victoria), and the University of Queensland
(http://www.rnaiglobal.org). These research institutions are all members of the
RNAi Global Initiative, an international collection of biomedical researcher groups
which has been established and coordinated by the Genomics Group of Thermo
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Scientific in order to increase the amount of work and therefore the progress being
made in the area of genome-wide RNAi studies (http://www.rnaiglobal.org).
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Figure 1.3 Whole genome screen (involving virus)
a. 384 well plates are seeded with host cells and siRNA library is introduced into
the cells by reverse transfection, that is the addition of the siRNAs in combination
with cell seeding. b. Approximately 48-72 hours later, virus is added to the plates.
c. Following an incubation period to allow sufficient time for infection and
replication, the plates are read by measuring fluorescence. This is done using a plate
reader which relies on spectroscopic principles to determine levels of fluorescence
in a sample. This gives us an indication of the level of virus present due to the
fluorescence of individual virus particles. The more virus in a sample, the greater
the fluorescence observed. d. Candidates are identified in the screen must be
verified by repeating the screen on a smaller scale in order to replicate the
experiment using only the genes that were identified to confirm their significance,
or repeated using separation of the smartpool siRNAs into individual siRNAs.
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Whole genome screening has identified a number of genes that are important for the
lifecycle of a wide range of viruses. One of these genes is α-COP (COPA)
Coatamer protein (Konig, Zhou et al. 2008), (Krishnan, Ng et al. 2008), (Karlas,
Machuy et al. 2010) (König, Zhou et al. 2008) (Li, Brass et al. 2009) (Mehle and
Doudna 2010). Within eukaryotic cells, the transport of proteins is controlled by a
secretory transport system consisting of a series of vesicular compartments
(Gorelick and Shugrue 2001)} (Figure 1.4). This system comprises 4 major
pathways: the import and quality control of proteins into the Endoplasmic
Reticulum (ER), the transport of proteins from the ER to the Golgi, intra-Golgi
transport, and transport from the Golgi (Béthune, Wieland et al. 2006)}. Vesicular
transport involves a number of steps including budding, transport, docking, and
fusion with target membranes. Formation of the secretory vesicles essential for this
transport requires the assembly of coat proteins of which there are three types – (1)
Clathrin-coated vesicles that play a role in the early secretory pathway for
endocytosis, (2) COPI vesicles, which export proteins from the ER, and (3) COPI-
coated vesicles that also function in the early secretory pathway (Beck, Ravet et al.
2009 2009)}. COPI-coated vesicle formation has four distinct steps; the assembly
of the coat, membrane deformation into a bud, budding off from the membrane, and
then disassembly of the vesicle membrane so that the coat components may be
recycled (Pinot, Goud et al. 2010).
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COPI- coated vesicles are protein and liquid carriers responsible for the
transport within the early secretory pathway, more specifically they are responsible
for the retrograde transport between the ER and the Golgi (Bethune, Wieland et al.
2006 2009). COPI coated vesicles are approximately 75-100 nm in diameter and,
upon leaving the ER, allow the forward movement of proteins to vesicular tubular
clusters (VTCs), followed by movement from the VTCs to the Golgi complex
(Pinot, Goud et al. 2010). It has also been shown that this retrograde trafficking may
play a role in controlling the content of the ER and therefore acts as a mechanism
by which the correct assembly of certain membrane proteins can be assured (Beck,
Rawet et al.). COPI vesicles have also been shown to play a role in the anterograde
transport from the ER (Gorelick and Shugrue 2001). There are four classes of COP
proteins, α, β, c, and d COP that together make up the COPI coatamer complex. The
protein components of these COPI-coated vesicles have been identified in a number
of high throughput siRNA screening papers involving virus as being an important
host factor during virus infection (König, Zhou et al. 2008 2008, Krishnan et al.,
2008, Li et al., 2009, Tai et al., 2009), (Karlas, Machuy et al. 2010) (Table 1.2).
The α-COP, or COPA protein in particular is of interest as an important
protein involved during virus infection due to its identification as an important gene
in a number of these publications (Watanabe, Watanabe et al. 2010).
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Figure 1.4 COPI - coated vesicle transport system.
The COPI vesicle pathway is a key component of the secretory transport system
within the cell. COPI- coated vesicles are protein and liquid carriers responsible for
the transport within the early secretory pathway. The COPI-coated vesicles upon
exiting the ER are responsible for the retrograde transport of protein between the
ER and the Golgi, which aids in controlling the content of the ER. COPI vesicles
also play a role in the anterograde movement of secretory protein from the ER to
the Golgi. Figure adapted from Lee et al., 2004.
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Secretory
ER protein
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transport
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transport
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Table 1.2 COPA has been identified in a number of whole genome siRNA
screens as a required host factor for a number of viruses.
Virus Virus family Publication
Influenza A
(H1N1)
Orthomyxoviridae Mehle et al., 2010, Konig et al., 2009,
Karlas et al., 2010, Brass et al., 2009
Dengue Virus Flaviviridae Brass et al., 2009
West Nile Virus Flaviviridae Brass et al., 2009
Hepatitis C Flaviviridae Tai et al., 2009, Li et al., 2009
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As outlined above, siRNAs can exist naturally within the cell due to the activity of
Dicer enzyme against long dsRNA. However, the RNAi pathway has also been
exploited in the last decade as a scientific tool, with synthetic siRNAs with
homology to genes of interest designed and then introduced artificially into a cell
(or organism) in order to silence individual genes (Castonotto et al., 2009). This has
permitted the function of those genes through gene loss-of-function to be deduced,
including the role of those genes during a number of processes that occurs in
response to virus infection. This has been done either on a small scale by targeting
single genes or on a whole genome scale using siRNA libraries to knock down the
expression of any gene within a cell (Chen, Du et al. 2007). By knocking down the
expression of a gene found to play a role in a pathway of interest or in the response
to a particular disease we can better understand the cellular pathway and responses
to disease to determine if it is a suitable target for intervention. This in turn will
help in the quest to develop new therapies to block these processes by increasing
our knowledge of the host genes that are important in the virus lifecycle.
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One of the issues arising with RNAi applications is how effectively the RNA can be
delivered into cell. Due to the size and charge of the siRNA molecules, which limit
their passage through the lipid membrane of cells, either electroporation (which
uses electric current to create holes in the cell membrane (Jafari, Soltani et al. 2012)
or a delivery vehicle is required to deliver synthetic siRNAs into a cell (Castonotto
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et al., 2009). The most common approach is to use lipid vesicle-based delivery
reagents which complex to form siRNA containing lipid vesicles which can pass
through the cell membrane into endosomes within the cytoplasm. Other issues
surrounding targeting of siRNAs is their low level of stability. This is particularly
significant when considering in vivo applications due to the degradation of siRNAs
in serum (Tiemann and Rossi). To help reduce the chance of siRNA degradation, a
number of modifications can be made to the siRNAs. These modifications include
adaptations to the molecular positioning of the siRNA to allow the resistance of
enzymatic hydrolysis such as replacement of the phosphodiester linkages to
phosphothioate at the 3’ end of the siRNA, and also the introduction of a methyl or
methoxyethyl group in order to increase the half-life of siRNAs within cultured
cells (Shim and Kwon). Other modifications include cholesterol conjugation,
aptamer-siRNA chimaeras, and the use of positively charged antibody conjugates
(Shim and Kwon).
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A major concern surrounding the use of RNAi technology, both in vitro and in vivo,
such as the introduction of siRNAs or shRNAs to silence the expression of genes in
order to dissect gene function, is the potential for off-target effects (Jackson and
Linsley 2010). This comprises the effects of the siRNAs on genes they are not
targeted against, potential toxic effects of both the siRNAs and the mechanisms by
which they are delivered, and potential negative effects due to the manipulation or
monopoly of the RNAi machinery (Jackson and Linsley 2010). For example, the
ability of siRNAs to compete with cellular miRNA, a class of post-transcriptional
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regulators, for the RNAi machinery and incorporation into the RISC is an important
off target effect. In order to avoid this, the smallest possible amount of siRNAs
should be introduced so as not to saturate the RNAi machinery (Castonotto et al.,
2009). Another intriguing off target effect is the immunostimulatory action of
siRNAs. It has been demonstrated that despite the design of siRNAs which should
allow them to bypass recognition by PRRs, some siRNAs, termed
immunostimulatory siRNAs (isRNAs) are potent stimulators of interferon (IFN)
production (Tiemann and Rossi 2009 2009). In activating the immune system this
off target effect may potentially be beneficial and may even be taken advantage of
for therapeutic purposes (Tiemann and Rossi 2009) Despite this, the
immunostimulatory effects of siRNAs are generally considered to be negative side
effects of most experiments employing RNAi-mediated gene silencing (Castonotto
et al., 2009).
To avoid or minimize these off-target effects, certain design strategies are
considered. These primarily include the introduction of nucleoside modifications to
reduce the potential for immunostimulatory action and also the inclusion of
differential end stability in the siRNA design to bias the introduction of the less
immunostimulatory strand over the other into the RISC machinery (Schlee,
Hornung et al. 2006).
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In addition to the role of RNAi in identifying candidate genes for new therapeutics,
it may also be used as a therapeutic itself, through its ability to silence specific
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genes. Despite its relatively recent discovery, RNAi-based therapeutics are already
being used in a number of clinical trials to treat a range of diseases. Clinical trials
have 4 phases, each with their own purpose. In Phase I trials, researchers tested an
experimental drug or treatment in a small group of around 20-80 people in order to
assess its safety in people for the first time, determine a safe dosage range, and
identify side effects. In Phase II trials, treatment is given to a larger group of around
100-300 people to determine whether it is effective and to further evaluate its
safety. In Phase III trials, the experimental study drug or treatment is given to an
even larger group of around 1000-3000 people to confirm its effectiveness, monitor
any side effects, compare it to commonly used treatments, and also to collect any
information that will permit the experimental drug or treatment to be safely used.
Finally, Phase IV trials, provide post marketing studies which outline additional
information about the risks and benefits associated with the use of the drug as well
as information for optimal use (www.clinicaltrials.gov). The use of RNAi as a
therapeutic provides potential alternative treatment options for a number of
diseases. Table 1.3 summarises current clinical trials involving RNAi therapeutics.
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Table 1.3 Summary table of current clinical trials involving RNAi
therapeutics.
Company Study Disease Trial Phase
Acuity
Pharmaceuticals
siRNAs targeting
vascular endothelial
growth factor
precursor (VEGF)
Age related
Macular
degeneration
Phase III
clinical trials
Allergen Inc. and
Merck-Sirna
Therapeutics
siRNAs against
VEGFR1
Age-related
macular
degeneration
Phase II
clinical trials
Alnylam
Pharmaceuticals
siRNAs targeting the
nucleocapsid
Respiratory
Synical virus
Phase II
clinical trials
Calando
Pharmaceuticals
siRNAs targeting the
ribonuclease
reductase (RRM2)
Solid tumours Phase I
clinical trials
City of Hope National
Medical Centre
shRNAs targeting the
Tat/Rev proteins of
the AIDS virus
AIDS lymphoma Phase I
clinical trials
Duke University siRNAs targeting the
Immunoproteasome
beta subunits LMP2,
LMP7 and MECL1
Metastatic
melanoma
Phase I
clinical trials
Opko Health Inc siRNAs targeting
VEGF
Diabetic macular
oedema
Phase II
clinical trials
Quark Pharmaeuticals siRNAs targeting Age-related
macular
Phase I
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RTP801 degeneration clinical trials
Quark
Pharmaceuticals
siRNAs targeting p53 Acute renal failure Phase I
clinical trials
Santaris Pharma LNA-anti miRNA
against miR-122
Hepatitis C Phase I
clinical trials
Trans Derm Inc. siRNAs targeting
keratin
Pachyonychia
congenita
Phase I
clinical trials
Figure adapted from (Tiemann and Rossi 2009).
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The delivery of siRNAs in vivo raises additional issues to those in vitro, including
the rapid degradation of siRNAs in the blood stream, the difficulties involving
targeting correct tissue, accumulation of siRNAs in tissues, poor cellular uptake and
rapid excretion (Shim and Kwon 2010). Currently, the delivery of siRNAs in vivo
takes two main approaches - systemic delivery and direct (local) delivery. The type
of delivery is dependent on the target. Systemic delivery involves the introduction
of siRNAs into the bloodstream and is useful in the treatment of diseases such
cancer as it is best suited to reach metastatic and haematological cancer cells (Shim
and Kwon). Local delivery however involves delivery of siRNAs directly to the
target tissue, for example direct injection into the eye, skin or muscle, intranasal
administration for delivery to the lungs, and direct injection into the central nervous
system. Local delivery is a much more cost effective way to deliver siRNAs as it
requires a much smaller dose of siRNA. It is also potentially more effective as it
reduces the time needed for the siRNA to reach its target site and therefore reduces
the chance of the siRNA being degraded (Shim and Kwon).
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Similarly to the use of siRNAs in vitro, the use of siRNA in vivo can also have off
target effects. One of the first concerns to be raised against the use of siRNAs
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followed an in vivo study by Grimm and colleagues in 2006 using mice, where
PolIII expressed shRNA which were delivered via tail vein injection resulted in
acute liver failure in many of the subject animals (Grimm et al., 2006). It was found
that the shRNAs had been processed into siRNAs which were then able to stimulate
off target effects by competing with the endogenous microRNAs within the cell for
the RNAi machinery (Tiemann and Rossi 2009).
The ability of siRNAs to induce a type I interferon response through the
activation of Toll-like receptors (TLRs) is also of concern in in vivo applications.
This was first demonstrated in 2005 in an experiment by Hornung and colleagues,
where they showed that in plasmacytoid dendritic cells (PDCs), an immune cell
which is involved in the detection of viral RNA and the production of type I IFN,
some siRNAs were able to stimulate the production of IFN, via interaction with
TLR7 (Hornung, Guenthner-Biller et al. 2005). This response was confirmed by
injecting siRNAs into TLR7 deficient mice. No increase in IFN production was
shown, indicating that the siRNAs were being recognized by TLR7. For this reason,
the TLR7-dependant recognition of siRNAs must be considered when using siRNA
as this interferon response may compromise the silencing ability of the RNAi
pathway (Hornung, Guenthner-Biller et al. 2005).
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There are a number of methods utilised by whole genome siRNA screens involving
viruses that enable the effect of knocking down gene expression on virus titre to be
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determined. Commonly used methods include staining for the presence of virus
with antibodies, a method used by Brass and colleagues in 2008 in their screen
looking at host factors necessary for HIV replication in human cell lines (Brass,
Dykxhoorn et al. 2008). During this experiment cells were stained post infection for
p24 produced from the HIV gag gene. This method was again used by Brass and
colleagues in 2009 in a screen involving influenza A H1N1, West Nile virus and
Dengue virus, where cells infected with H1N1 were fixed then stained with an anti-
HA antibody followed by an Alexa Fluor 488 secondary antibody and cells infected
with either West Nile Virus and Dengue virus were immune-stained using an
antibody to detect viral E-protein (Brass, Huang et al. 2009). This approach was
also used by Krishnan and colleagues in their 2008 study involving West Nile virus,
where they quantitated virus infection by microscopy-based observations of
samples immunostained for viral envelope protein and by Li and colleagues in 2009
where cells were stained and imaged for the expression of Hepatitis C virus core
protein as a measure of viral titre (Krishnan, Ng et al. 2008), (Li, Brass et al. 2009).
Other studies such as those performed by Konig and colleagues in 2008 involving
HIV, Tai and colleagues in 2009 involving Hepatitis C, and again by Konig and
colleagues in 2009 involving H1N1 relied on luciferase expressing viruses to
determine viral titre in response to silencing of host genes (Konig, Zhou et al.
2008), (Tai, Benita et al. 2009), (Konig, Stertz et al. 2010). The development of
viruses which express a fluorescent protein is a convenient way to determine viral
titre in such screens, and one way to do this is to use reverse genetics to engineer a
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Green Fluorescent Protein (GFP)-expressing H5N1 virus. (Brass, Huang et al.
2009), (Li, Brass et al. 2009), (Tai, Benita et al. 2009), (Konig, Stertz et al. 2010).
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Reverse genetics is a system which allows the creation of infectious viruses entirely
from cloned cDNA (Hoffmann, Neumann et al. 2000). Unlike previously used
methods, the reverse genetics system designed by Hoffman and colleagues utilizes
an 8 plasmid system, which each contain a different viral cDNA fragment (HA,
NA, M, NS, NP, PB1, PB2 and PA) needed to rescue an infectious virus
(Hoffmann, Neumann et al. 2000).  This 8 plasmid-based expression system works
by generating a bidirectional transcription construct with cDNA that encodes one of
the 8 gene fragments and flanked by RNA polymerase promoter (PolI) for vRNA
synthesis and also an RNA polymerase II promoter (PolII) for mRNA synthesis,
together with viral RNA (vRNA) and protein-expression constructs for the other 7
gene segments that make up a complete influenza A virus (Hoffmann, Neumann et
al. 2000). These 8 expression plasmids which each contain one copy of one of the 8
viral cDNAs are then transfected into a co-culture of MDCK and 293T cells and left
for 72 hours. This cell co-culture approach is designed to maximize virus
production. The virus is produced within the 293T cells, and then infects the
MDCK cells where it more efficiently replicates. The virus can then be harvested
from the cell supernatant (Hoffmann, Neumann et al. 2000) (Figure 1.5).
In addition to the generation of infectious virus particles, reverse genetics has been
used in the influenza field for a number of diverse applications. This includes the
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development of LAIV by introducing attenuating mutations into the influenza virus
genome. This is done using a number of ways, including by introducing mutations
into the polymerase gene to produce a temperature-sensitive phenotype, by
modulation of the NS protein in order to generate a virus unable to prevent the
induction of a cellular antiviral state, and lastly by disrupting the cytoplasmic tail of
the M2 protein in order to generate a virus that cannot efficiently assemble (Steel).
Similarly, it has been used to study the pathogenesis of influenza viruses. An
example of this is a study by Hatta and colleagues where they used reverse genetics
to generate both a highly pathogenic influenza A virus A/Hong Kong483/97
(HK483) and a low pathogenic influenza A virus A/Hong Kong 486/97 and a series
of reassortant viruses using genetic material from these two strains. They then
conducted pathogenesis studies in mice to determine the virulence factors (Imai,
Watanabe et al. 2012).
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Figure 1.5 Generation of GFP expressing Influenza A H1N1 virus using the 8-
plasmid reverse genetics system. The 8 individual gene segments that make up the
Influenza A genome are incorporated into PHW2000 plasmids.  NS is modified to
express a GFP protein. 8 plasmids are transfected into a co culture of MDCK and
Hek293T cells using Fugene transfection reagent. NS-GFP expressing H1N1 virus
is assembled within the Hek293T cells and multiplied within the MDCK cells.
Figure adapted from (Hoffmann, Neumann et al. 2000).
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This project aims to employ the RNA interference (RNAi) pathway in order to
characterise the role of COP-I vesicles in the host interaction with highly
pathogenic avian influenza H5N1. By using siRNAs to knockdown the expression
of host genes identified as being implicated during virus infection, it is hypothesised
that virus replication can be inhibited. Specifically, my hypothesis is that silencing
host genes implicated in the virus lifecycle using siRNAs will inhibit the growth of
highly pathogenic Avian Influenza H5N1virus in vitro.
My project objectives are as follows;
 Identify host gene candidates from existing whole genome siRNA screen
publications involving low pathogenic viruses.
 Identify host gene candidates by measuring the expression a subset of host
genes in response to infection with highly pathogenic Avian Influenza
H5N1 in HeLa cells using Human α, β Interferon qPCR arrays.
 Contribute work to the development of a GFP-expressing PR8 H1N1 virus
using a reverse genetics system for use in determining the ability of siRNAs
to inhibit a GFP expressing H5N1 virus in vitro.
 Determine the optimal cell line for both transfections with siRNAs and
infection with Influenza A H5N1 virus.
 Demonstrate silencing of identified genes in HeLa cells using smartpool
siRNAs.
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 Measure the effect of silencing identified genes on virus growth in vitro
using  TCID50 assays
 Determine the effect of silencing identified genes on virus growth in vitro
using confocal microscopy.
These research aims will provide us with a greater understanding of the role of
important host factors in the lifecycle of highly pathogenic avian influenza and
aim to provide easier and potentially more cost effective means of visualizing
virus growth.
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2. Materials and Methods
2.1 Materials and equipment
Table 2.1 Materials and equipment suppliers.
Materials and equipment Supplier
Dulbecco's modified Eagle’s medium
(DMEM), Eagle’s modified medium
(EMEM)
AAHL tissue culture services
Ambion Silencer siRNA Construction
Kit, MicroAmp Fast Optical 96-Well
Reaction Plate, optical adhesive film and
SYBR Green PCR master mix
Applied biosystems/Ambion
(Mulgrave. Victoria, Australia)
SnapStrip* 8-strip 200μl PCR tubes Astral Scientific (Gymea, NSW)
Falcon tubes BD Bioscience (New Jersey, USA)
Chloroform BDH (Corston. Bath, UK)
75 cm2 flasks Corning (Lowell, USA)
Vectashield mounting medium was
supplied by Vector Laboratories
(Peterborough, UK). COPA smartpool
short interfering RNA siRNA
Dharmacon (Lafayette, CO, USA)
Microcentrifuge tubes Eppendorf (Hamburg, Germany)
Foetal calf serum (FCS) HyClone Thermo scientific (Delaware,
USA)
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Opti-MEM I Reduced Serum Medium
(1×), L-glutamine, 2×L15 media and
Trypsin/Versene (TV) x10, Poly I:C and
Lipofectamine 2000 and Big Dye
Terminator reagent
Invitrogen (Mulgrave, Victoria,
Australia)
Ethanol and isopropanol MERCK (New Jersey, USA)
Sodium pyruvate, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES),
and MEM non-essential amino acids
MP Biomedicals (Karrinyup, Western
Australia).
Tissue culture plates (6, 12, 24 and 96
well), 96-well V-bottom plates
Nunc (New York, USA).
Phosphate Buffer saline (PBS) and
tryptone
Oxoid (Hampshire, United Kingdom)
JM109 competent cells, 10× reverse
transcription buffer, magnesium chloride
(MgCl2), dNTP, RNasin, random
primers, RNAse free water and reverse
transcriptase
Promega (Madison, WI)
Fugene6 transfection reagent Roche Applied Sciences (Indianapolis,
USA)
Sarstedt tubes. Sarstedt (Nümbrecht, Germany)
Penicillin, streptomycin, gentamycin,
dimethyl sulfoxide (DMSO), 2-
Sigma-Aldrich (Castle Hill. NSW,
Australia)
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mercaptoethanol, fungazome, TRI-
reagent, ampicillin sodium salt, 1.8%
agarose, amplification grade DNase I,
10× DNase reaction buffer, Trypan Blue
stain, 0.1% Triton X-100 and 4′, 6′-
Diamidino-2-Phenylindole (DAPI)
Commercial Ross 308 embryonated
chicken eggs
Turi Foods Pty Ltd (Bannockburn.
Victoria, Australia)
RNeasy Mini Kit and Plasmid Maxi Prep
Kit
Qiagen (Texas, USA)
Leica DFC310FX Leica Microsystems (Wetzlar,
Germany)
L-1-tosylamido-2-phenylethyl
chloromethyl ketone (TPCK) Trypsin
Worthington Biochemical Corporation
(New Jersey, USA)
2.2 Buffers, solutions and other reagents
The following media were used in this study and were made according to the
manufacturer’s guidelines by Tissue Culture services, CSIRO, AAHL, Geelong:
Phosphate buffered saline (PBS)HEPES, DMEM, EMEM fetal calf serum (FCS),
Trypsin/Versene (TV) ×1
The following media were made as follows;
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Easy flu medium: Opti-MEM I Reduced Serum Medium (1x) supplemented with
100 μg/mL penicillin, 100 μg/mL streptomycin. Freeze media: FCS supplemented
with 10% dimethyl sulfoxide (DMSO)
Human embryonic kidney (HEK) 293T cell growth media: DMEM
supplemented with 10 % FCS, 2 mM L-glutamine, 1 mM MEM sodium pyruvate,
100 μM MEM non-essential amino acid, 5 mM HEPES, 100 μg/mL penicillin, 100
μg/mL streptomycin, 55 μM 2-mercaptoethanol.
Luria-Bertani (LB) broth: H2O supplemented with 0.5 % w/v yeast extract, 1 %
w/v NaCl and 1 %w/v tryptone.
MDCK cell growth media: RPMI supplemented with 10 % FCS, 2 mM L-
glutamine, 1 mM MEM sodium pyruvate, 100 μM MEM non-essential amino acids,
5 mM HEPES, 100 μg/mL penicillin, 100 μg/mL streptomycin, 55μM 2-
mercaptoethanol
MDCK maintenance media/viral growth media: RPMI supplemented with 100
μg/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, and 5 mM HEPES.
Reverse genetics maintenance media: OPTI-MEM 1 medium supplemented with
5 % FCS, 100 μg/mL Penicillin, and 100 μg/mL streptomycin
Reverse transcription master mix (1×): 2 μL 10x Amplification buffer (AMP), 2
μL 25 mM MgCl2, 2 μL 10 mM dNTP, 1 μL RNasin, 1 μL random primers, 0.5 μL
reverse transcriptase and 0.5μL distilled H2O (dH2O)
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Transfection media: EMEM supplemented with 10 % FCS, 2mM L-glutamine,
1 mM MEM sodium pyruvate, 100 μM MEM non-essential amino acids, 5 mM
HEPES, 55 μM 2-mercaptoethanol
2.3 Cell culture and bioassays
2.3.1 Continuous cell lines
Cell lines were cultured in 75 cm2 flasks in a Thermo Scientific Forma series II
water jacket CO2 incubator at 37 °C (Thermo Scientific. Waltham, USA).  HeLa
and Hep2 cells were maintained in Eagle’s minimal essential media (EMEM)
supplemented with 10 % FCS, 2 mM glutamine, 2.5 % sodium bicarbonate,
penicillin (100 U/mL), streptomycin (100 μg/mL) and 10 mM N-
2hydroxyethyalpiperazine-N’-2-ethanesulfonic acid (HEPES). A549 and U373 cell
lines were maintained in Dulbecco’s modified Eagle’s media (DMEM). MDCK
cells were maintained in RPMI media and DMEM growth media. Hek293T cells
were maintained in DMEM media. Cells were routinely passaged every 3-5 days as
required by harvesting by washing with PBSA and then incubating for 5 min at 37
°C with 2 mL of trypsin before being collected into 5 mL of growth media. Cells
suspensions were then centrifuged at 1200 × g and resuspended in 1 mL of growth
media and counted using a haemocytometer. Cells were reseeded using
approximately 20-30 % of the harvested cells. Cells were passaged up to 20
passages.
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2.3.2 Cells for liquid nitrogen storage
Cell cultures were washed and trypsinised and the cell suspension collected in
separate 50 mL falcon tubes and centrifuged at 1200 × g for 5 min. The culture
supernatant was discarded and cells resuspended in 1 mL freeze media. Cells were
counted using a haemocytometer and the concentration adjusted to 2 × 106 cells/mL.
Aliquots (1 mL) were dispensed into cryogenic vial and placed in liquid nitrogen
for storage.
2.3.3 Thawing cells
Cells were thawed by placing cryogenic tubes into a 37 ˚C water bath. Cells were
added drop wise into the 15 mL falcon tube containing 9 mL of appropriate growth
media. Cells were then centrifuged at 1200 × g for 5 min at 4 ˚C. The supernatant
was discarded and cells re-suspended in 1 mL growth media. Cell suspensions were
then transferred into a 75 cm2 culture flask and incubated at 37 ˚C, 10 % CO2.
2.3.4 Cell counting
Cells were counted by combining 10 μL of cell suspension with 90 μL of Trypan
Blue to exclude dead blue stained cells. 10 μL of this mixture was placed on a
haemocytometer in order to count the number of cells.
2.4 Nucleic acid techniques
2.4.1 siRNA transfections
HeLa cells were seeded at 0.5 ×105 cells per well in a 24 well plate in complete
growth media. After 24 h, media was changed to growth media without antibiotics
and the cells transfected with 20 pmol of Dharmacon COPA smartpool short
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interfering (si)RNA per well (Table 2.3). Cells were transfected using the
Lipofectamine 2000 method as per the manufacturer’s instructions. The cells were
left to incubate with the siRNA complexes for 4 h before being removed and media
being replaced with complete growth media.
2.4.2 Isolation of RNA
RNA was extracted from cell culture using Tri-Reagent according to the
manufacturer’s instructions. Briefly, cells were lysed by adding Tri-Reagent to
wells after cells had first been washed using PBSA then the RNA purified by
adding 200 μL of chloroform per mL of Tri-Reagent.  Tubes were then shaken
vigorously for 15 sec and left to incubate at room temperature (RT) for 5 min.
Following this, the tubes were centrifuged at 12,000 × g for 15 min at 4 °C and the
aqueous phase transferred to a new tube. To this, 500 μL of isopropanol was added
and contents mixed by gently inverting the tubes for 1 min. Samples were then
incubated at -20 °C for 1 h and centrifuged at 12,000 × g for 20  min at RT.  The
supernatant was then removed and the pellet washed with 500 μL of 75 % ethanol
and centrifuged at 7,500 × g for 5 min at 4 °C. The pellet was then briefly air dried
before being dissolved in 30 μL of nuclease free water. Samples were heated at 55
°C for 15 min to facilitate dissolution.
2.4.3 DNAse treatment of RNA samples.
Extracted RNA was made up to 30 μL using nuclease free water and subjected to
treatment with DNAse-1 kit according to the manufacturer’s instructions. Briefly, 1
μg of RNA was made up in 8 μL of RNase free water. To this, 1 μL of 10 ×
reaction buffer and 1 μL of DNAse 1(1 unit/μL) was added. Contents were mixed
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and incubated at RT for 15 min. Following this incubation, 1 μL of stop solution
was added and tubes incubated at 70 °C for 10 min to denature both the DNAse 1
and the RNA before being placed on ice. The DNAse treated RNA (1 μg) was then
stored at -80 °C until required.
2.4.4 Reverse transcription PCR (RT-PCR)
Complementary DNA (cDNA) was created by reverse transcribing DNAse-treated
RNA by combining 1 μg of DNAse treated RNA, 2 μL 25 mM MgCl2, 2 μL 10 ×
amplification (AMP) buffer, 2 μL 10mM dNTPs, 2 μL reverse transcriptase and 0.5
μL nuclease free water. Reactions were then incubated at 42 °C for 1 h followed by
a 10 min, 95 °C inactivation step using an Eppendorph vapoprotect thermocycler
(Eppendorph. Hamburg, Germany). Finally, cDNA was diluted 1:10 with RNAse
free water and stored at - 20 °C for subsequent analyses.
2.4.5 DNA and RNA quantification
DNA and RNA was quantified using a Nano drop® ND-100 spectrophotometer.
Analyses were carried out by applying 1 μL of nuclease free water as a blank
reference and then by measuring a 1 μL aliquot of each individual RNA or DNA
sample. Samples were defined as having acceptable RNA contamination levels
when their 260:280 nm absorbance ratios were between 1.7 and 1.9.
2.4.6 Polymerase chain reaction (PCR)
PCR amplification was performed in an Eppendorph VapoProtect thermocycler
using Astral Scientific SnapStrip* 8-strip 200 μL PCR tubes. To each tube, 10 μL
Gotaq green Buffer, 2.5 μL 10 μM forward primer, 2.5 μL 10 μM reverse primer
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(Table 2.2), 0.25μL DNA polymerase, 2.5μL DNA template and 32.2 μL nuclease
free water were added. The PCR cycling conditions were as follows. Step 1, 94 °C
for 5 min. Step 2, 94 °C for 1 min. Step 2 – 4 repeated 35 cycles. Step 3, 55 °C for 1
min. Step 4, 72 °C for 1 min. Step 5, 72 °C for 15 min. Step 6, for 4 °C stored.
2.4.7 Electrophoretic separation of DNA
PCR products were run on a 1 % agarose gel using a BioRad Gel dock and a
BioRad Powerpac Basic system (Gladesville.  NSW, Australia). Products were run
for approximately 1 h at 100 V. Resulting bands were visualized using a Syngene
G: Box Ultraviolet light box (Syngene. Sydney, Australia) before being
photographed or excised from gel for further analysis.
2.4.8 Ligations of PCR products into plasmid vectors
The NS-GFP gene segment obtained from Aldolfo Garcia-Satre (Department of
Microbiology, Global Health and Emerging Pathogens Institute and Department of
Infectious diseases, Mt. Sinai, New York) was ligated into a PHW2000 plasmid; a
generous gift of Richard Webby, St. Jude Children’s Research Hospital. To each
reaction was added 2 μL of 10 × buffer, 50 ng vector (3 kb), 50 ng insert, 1 μL of
T4 Ligase and RNase free water to 20 μL. Reactions were incubated at 25 °C for 1
h before being transformed into competent JM109 E coli cells.
2.4.9 Plasmid DNA preparation and transformation of E coli.
The NS-GFP containing PHW2000 plasmid was amplified using JM109 E coli
bacteria grown in LB broth. Plasmid DNA (10 ng) was added to 30 μL of
competent E. coli cells and mixed before being placed on ice for 30 min. Following
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this, cells were heat shocked for 45 min in a 42 °C water bath before being placed
immediately on ice for 2 min. 900 μL of room temperature LB broth was added to
the competent cells and incubated for 60 min at 37 °C. Cells were then pelleted by
centrifugation at 2000 × g for 5 min using a Thermo Scientific Heraeus megafuge
16R centrifuge. Pelleted cells were resuspended in 100 μL of LB media and
pipetted and streaked onto a LB/amp plate and placed upside down at 37 °C to
allow bacteria to grow overnight. A single colony was picked from the LB/amp
plate and added to 2 mL of LB medium containing 100 μg/mL Amp and left at 37
°C for approximately 8 h. This starter culture was then diluted 1/500 with LB/Amp
medium and grown at 37 °C for 12-16 h. Plasmid DNA was then harvested from the
bacterial pellet using a Qiagen Plasmid Maxi Prep Kit as per the manufacturer’s
instructions. Briefly, the pellet was resuspended in 10 mL of buffer P1 and then
10mL of buffer P2 was added. This was mixed thoroughly by inversion and then
incubated at room temperature for 5 min. Following this, 10 mL of chilled buffer P3
was added to the lysate which was then poured into the barrel of the QIAfilter
cartridge and then incubated at RT for 10 min. The lysate was then plunged through
the filter and 2.5 mL of buffer ER added. This mixture was incubated on ice for 30
min. The lysate was then collected in a QIAGEN-tip which was washed twice with
30 mL of buffer QC and then the DNA was eluted using 15 mL of buffer QN. The
DNA was then precipitated by adding 10.5 mL of RT isopropanol and centrifuged
immediately at 15,000 × g for 30 min at 4 °C. The supernatant was then decanted
and pellet washed in 100 % ethanol. The pellet was air dried and resuspended in
endotoxin-free buffer TE.
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2.4.10 Sequencing
Plasmid DNA was sequenced by Kelly Davies at CSIRO AAHL using the Applied
Biosystems 3130xl Genetic Analyser and Big Dye Terminator reagent. To a
SnapStrip PCR tube 1 μL of Big Dye Premix (v3.1) x ready reaction premix, 3.5 μL
(5×) reaction buffer, 300 ng template dsDNA, 1 μL E GFP primer (Table 2.2) (3.2
pmol) and RNAse free water to 20 μL were added. The PCR cycling conditions
were as follows: Step 1, 96 °C for 1 min. Step 2, 96 °C for 10 sec. Step 2 – 4
repeated 30 cycles. Step 3, 50 °C for 5 sec. Step 4, 60 °C for 4 min. Step 6, 4 °C
stored.
2.5 Virology methods
2.5.1 Influenza H1N1 strains
Influenza A strain A/PuertoRico/8/34 (PR8wt) was obtained from John Stambas –
Deakin University. Virus stocks were 2 × E8 PFU.
2.5.2 Influenza H5N1 strains
A/chicken/Vietnam/008/2004 H5N1 was obtained from Chrissy Rootes CSIRO
Australian Animal Health Laboratory (Geelong, Victoria) via the Regional Animal
Health Centre, Ho Chi Minh City, Vietnam. Virus stocks were grown in
embryonated chicken eggs. Virus stocks were 5 x E8 PFU.
2.5.3 Virus titration assays, tissue culture infectious dose 50% (TDIC50)
Virus was serially (1:1) diluted in complete growth media and added to wells in a
96 well plate containing 0.6 × 104 cells per well using HeLa, Hep2, A549 or U373
cells obtained from tissue culture at CSIRO Australian Animal Health Laboratories
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(Geelong, Victoria) in order to obtain virus quantifications through measurements
of cytopathic effects. Supernatants collected from wells containing infected cells
were serially diluted (10-fold) using PBS and incubated in virus growth media on
Vero cells for 5 days at 35 °C, 5% CO2.
2.5.4 Calculations of TCID50
Cells were examined 5 days post infection for signs of cytopathic effects (CPE).
Cells were then given a TCID50 score based on the virus dose at which 50 % of the
treated wells exhibited signs of CPE. 10-fold dilutions of medium aliquots were
made in PBS and added to a 96-well tissue culture plate containing Vero cells (9 ×
103 cells/well) in growth medium. Plates were incubated for 5 days at 37 °C, 5 %
CO2 and scored for cytopathic effect. The infectious titre was calculated by the
method of Tian and colleagues (Tian, Cheng et al. 2011).
2.5.5 Infections of HeLa cells
Cells seeded in growth media on coverslips at 0.5 × 105 cells per well were
incubated at 37 °C for 48 h post transfection before being infected with H5N1 at a
dilution of 1:10,000 of a stock concentration of 5 x E8 PFU in HeLa cells. H5N1
virus was added to cells in complete growth media. Supernatants from virally-
infected cells were harvested for Haemagluttination (HA) assay and TCID50 assays
24 h post-infection and cells fixed using 4 % paraformaldehyde solution for 2 h
before being rinsed and stored in PBSA at 4 °C until required for analysis.
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2.5.6 Reverse genetics
A co-culture of MDCK cells and Hek293T cells were seeded in Easy Flu media at a
2:1 cell number ratio in 6 well plates, at a number of cells sufficient to achieve
confluence after 24 h. 10 ng of the each of the 8 individual PHW2000 plasmids
containing one of the 8 influenza A viral gene segments (HA, NA, PB1, PB2, NP,
M, PA from a PR8 H1N1virus and the modified NS segment) were added to 1 mL
of Optimem media containing 16 μL Fugene 6 transfection reagent and left for 30
min to form complexes before being added to the MDCK/Hek293T cell monolayer.
The PHW2000 vector contains a 225 bp human pol I promoter and a 33 bp murine
terminator sequence which is separated by two BsmBI sites. These promoter and
terminator sequences are flanked by truncated immediate-early human
cytomegalovirus promoters and by the polyadenylation site of the gene which
encodes bovine growth hormone. Growth media was removed prior to the addition
of the plasmid complexes. The cells were left to incubate with the viral plasmid
DNA complexes for 6 h before being removed and media being replaced with Easy
Flu media. Reverse genetics maintenance media containing 1 μL/mL of trypsin was
added 18 h after transfection to aid virus cleavage from MDCK cells. Cell
supernatants were then collected 48 h later for use in HA assay and to harvest virus
for passage through eggs.
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2.5.7 Propagation of influenza virus in eggs
Both the H1N1 PR8 and H5N1 influenza A viruses were propagated using
embryonated 10-day old specific pathogen-free chicken eggs. Eggs were candled
using a small torch to determine viability and to find the edge of the air sack. A
small hole was made above the air sack and 100 μL of a 1:100,000 dilution of a 2 ×
E8 PFU virus stock injected into the allantoic fluid. The eggs where incubated for
48 h at 35 ˚C and then placed at 4 ˚C overnight to sacrifice the embryo. The shell
above the air sack was removed and allantoic membrane peeled back. The allantoic
fluid was collected using a 10 mL Pasteur pipette and placed into a chilled 15 mL
falcon tube. Allantoic fluid was centrifuged at 2000 × g for 5 min to pellet red blood
cells (RBC) and debris. A HA assay was performed to determine the presence of
virus in the clarified allantoic fluid, while the remaining allantoic fluid was store at
-80 ˚C.
2.5.8 Haemagluttination Assay
Serial (1:1) dilutions of allantoic fluid taken from both the eggs used to grow virus
stocks and cell supernatants from the reverse genetics experiments were performed
using into PBSA in 96 well plates. To each well, 50 μL of a chicken red blood cell
solution in PBSA was added. The plate was then left to incubate for 30 min at RT
before being read. Wells positive for virus were observed to have a red matt
appearance, whilst wells negative for virus had a red ‘dot’ appearance due to the
sinking of the red blood cells within the well.
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2.5.9 MDCK infections (virus growth)
MDCK cells obtained from tissue culture at CSIRO Australian Animal Health
Laboratories were infected using 1 mL of supernatant harvested from the reverse
genetics plates to check for positive virus rescue. Growth media was removed and
400 μL of supernatant was added to wells. Plates were then tilted at 15 min
intervals to ensure even dispersal of supernatant across the cell monolayer and
MDCK virus growth media was added 1 h after supernatant and incubated at 37 °C.
GFP expression was measured by imaging and photographing infected cells with
fluorescence microscopy using a Leica DFC310FX (Leica Microsystems. Wetzlar,
Germany) 24 h and 48 h post infection.
2.6 Quantitative gene analysis
2.6.1 Quantitative- real time-polymerase chain reaction (Q-RT-PCR)
The quantitation of gene expression was carried out on Applied Biosystem Step
One plus Real Time PCR System and used the comparative threshold cycle (ΔΔCt)
method to determine the fold change gene expression, according to the
manufacturer’s instructions. Cycling conditions were as follows; 1 × cycle 50 ˚C for
2 min followed by 95 ˚C for 10 min, 40 × cycles 95 ˚C for 15 sec followed by 60 ˚C
for 1 min. Primers (Table 1) were designed using Geneworks oligo design website
and designed within the Open Reading Frame (ORF). Samples were measured in
triplicate in 25 μL reactions using SYBR Green master mix according to the
manufacturer’s instructions in96-well reaction plates. Optical adhesive film was
applied to the plates which were then briefly centrifuged at 1200 × g for 1 min.
Relative gene expression was calculated using the ΔΔCt method. Gene levels were
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normalized against the housekeeping gene control glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH).
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cDNA used in these arrays were prepared using RT2 First Strand Kit as per the
manufacturer’s instructions. Briefly, RNA was combined with GE buffer and
nuclease-free water and incubated at 42 °C for 5 min before being placed
immediately on ice. Following this, the RNA was added to 10 μL of a reverse
transcription mix including 5 × buffer, RE3Reverse transcription mix and nuclease-
free water. This was then incubated at 42 °C for 15 min before stopping the reaction
by incubating the solution at 95 °C for 5 min. Following this the reaction was made
up to the appropriate volume with nuclease free water and incubated on ice until
proceeding with quantitative real-time PCR (QRT-PCR). QRT-PCR was performed
by placing cDNA and master mix into each well of the 96 well plates and running
plates in a thermocycler. Cycling conditions were as follows; 1 × cycle 94 ˚C for 2
min followed by 40 × cycles of 94 ˚C for 15 sec, 60 ˚C for 30 sec.  All QRT-PCR
runs were followed by melt-curve cycles.
2.6.3 Statistical analyses
Two-tailed Student t tests were used to determine statistical differences between
two groups of data. Experimental values differing significantly from the control
values were indicated by levels of significance as follows, *p<0.02.
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2.7 Microscopy
Confocal microscopy was performed by Paul Monaghan at CSIRO AAHL in
Geelong using a Leica sp5 confocal microscope.
2.7.1 Cell fixation
HeLa cells grown on coverslips were first fixed with 4 % paraformaldehyde
overnight then washed twice for 5 min with PBSA and permeablized with 0.1 %
Triton X-100 in PBS for 20 min.
2.7.2 Antibody staining
Non-specific binding sites were blocked with block buffer (5 % bovine serum
albumin (BSA) in tris-buffered saline) for 30 min. Cells were washed with twice for
5 min with PBSA and incubated with primary antibodies at a concentration of
1:1000 in block buffer for 1 h, washed again twice with PBSA, and incubated with
the appropriate species specific, Alexa-fluor conjugated secondary at 1:1000
antibody (also in block buffer) for 1 h. The cells were washed and the nuclei labeled
with 4′, 6′-Diamidino-2-Phenylindole (DAPI) in dH2O for 10 min and then washed
with dH2O. The coverslips were mounted in Vectashield mounting medium for
fluorescence (Vector Laboratories) and sealed with clear nail varnish.
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Table 2.2 Oligonucleotides used in this study
Name Sequence MW TM
CXCL10 R 5’ – 3’ GCAGGTACAGCGTACGGTTC 6158 56
CXCL10 L 5’ – 3’ CAGCAGAGGAACCTCCAGTC 6096 56
IL1β R 5’ – 3’ AAGGCCTTGCTGTAGTGGTG 6164 54
IL1β L 5’ – 3’ GAAGVTGATGGCCCTAAACA 6135 52
IL6 R 5’ – 3’ CATTTGTGGTTGGGTCAGG 5906 51
IL6 L 5’ – 3’ AGTGAGGAACAAGCCAGAGC 6209 54
CCL5 R 5’ – 3’ TGTACTCCCGAACCCATTTC 5988 52
CCL5 L 5’ – 3’ TACACCAGTGGCAAGTGCTC 6102 54
CCL2 R 5’ – 3’ AGGTGACTGGGGCATTGAT 5924 51
CCL2 L 5’ – 3’ GCCTCCAGCATGAAAGTCTC 6062 54
TNF R 5’ – 3’ AGATGATCTGACTGCCTGGG 6173 54
TNF L 5’ – 3’ CTGCTGCACTTTGGAGTGAT 6139 52
GAPDH R 5’ – 3’ CTTTGGTATCGTGGAAGGACTC 6781 55
GAPDH L 5’ – 3’ AGTAGAGGCAGGGATGATGTTC 6880 55
COPA R 5’ – 3’ CAGTCGTGGAGTAAACTGGG 6022 54
COPA L 5’ – 3’ CGATCGTGGAGTAAACTGGG 6222 54
EGFP R 5’ – 3’ ACGAACTCCAGCAGGACCATG 6409 56
EGFP L 5’ – 3’ GCAGAAGAACGGCATCAAGGT 6513 54
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Table 2.3 SMARTpool siRNA sequences
Name Sequence Mol. Wt. Ext. Coeff.
Si Genome
SMARTpool
siRNA D-
011835-01
COPA
ACUCAGAUCUGGUGUAAUA 13,358.0
(g/mol)
383,946
(L/mol.cm)
Si Genome
SMARTpool
siRNA D-
011835-02
COPA
GCAAUAUGCUACACUAUGU 13,358.0
(g/mol)
381,632
(L/mol.cm)
Si Genome
SMARTpool
siRNA D-
011835-03
COPA
GAUCAGACCAUCCGAGUGU 13,403.0
(g/mol)
368,994
(L/mol.cm)
Si Genome
SMARTpool
siRNA D-
011835-04
COPA
AGUUGUACCUCAGCAAUU 13,373.0
(g/mol)
373,978
(L/mol.cm)
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Results chapter 1.
The impact of silencing coatomer protein complex, subunit alpha on avian
influenza H5N1 influenza A infection in vitro.
	4:85*;):/54
Viruses are pathogens which require the presence of a number of host factors in
order to replicate (Campbell et al., 2006).  Not only must they interfere with cellular
membrane transport to gain entry to the cell, they must then replicate within the cell
making use of the cells own machinery and proteins before releasing their progeny
(Webster, Bean et al. 1992).Coatamer protein complex, subunit alpha (COPA) is a
host factor identified by whole genome siRNA screens as being implicated in the
lifecycle of a number of genetically different viruses, including low pathogenic
influenza A H1N1 virus, West Nile virus, Dengue virus and HIV-1 (Mehle and
Doudna 2010), (Konig, Zhou et al. 2008), (Karlas, Machuy et al. 2010), (Brass,
Huang et al. 2009), (Tai, Benita et al. 2009), and (Li, Brass et al. 2009). Cureton
and colleagues have recently published work which demonstrated that disruption of
COPI function using smartpool siRNAs targeting COPI genes inhibited the early
stage of vesicular stomatitis virus (VSV) replication. The aim of this experiment
was to dissect which replication stage(s) were affected by coatamer inactivation and
they were able to demonstrate by first transfecting cells with smartpool siRNAs
targeting the COPI genes and then infecting with VSV, that COP depletion for 12 h
was able to inhibit virus entry and interfere with viral gene expression. They further
demonstrated a role for COPI function by inhibiting its function using Brefeldin A
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(BFA), a chemical inhibitor of COPA function. Using BFA they were able to show
that short-term treatment (1 h) with BFA inhibited VSV gene expression and that
long-term treatment (12 h) with BFA was able to block the entry of the virus. They
concluded that prolonged coatomer inactivation interrupts cellular endocytic
transport which indirectly impairs VSV entry and that this provides an explanation
for why COPI coatomer is regularly identified by whole genome siRNA screens as
being a cellular host factor that is required by a number of viruses. To further
support the findings of these screen papers which suggest that COPI protein may
play an important role in the replication of a number of genetically diverse viruses
including low pathogenic influenza A, my project looks at the impact of inhibiting
COPA protein using siRNAs on the growth of a highly pathogenic influenza A
virus A/chicken/Vietnam/008/2004 H5N1 virus, otherwise known as avian
influenza virus or ‘bird flu’. COPI, although implicated as important for LPAI, has
not yet been implicated as being an important host factor for the replication of
highly pathogenic avian influenza A/chicken/Vietnam/008/2004 H5N1, as existing
studies have not looked at any biological safety level 3 (BSL-3) pathogens, the
classification within which H5N1 is categorised. Further investigation is warranted
here.
Akin to COPA, cytokines are a class of host factors associated with impacting the
virus-host interaction. Cytokine production is particularly relevant to avian
influenza virus infection, and has been hypothesized to play a detrimental role
during highly pathogenic influenza infection (Tisoncik et al., 2012). Although
recent publications such as the 2007 publication by Salamon and colleagues place
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doubts as to the importance of the cytokine response in the pathogenicity seen
towards pathogenic influenza A/chicken/Vietnam/008/2004 H5N1, further study of
the cytokine response to infection with this virus may lead to the identification of
new host targets for therapeutic design (Salamon et al., 2007).
With the identification of targets, we then need to find ways to inhibit their
expression in order to determine whether or not they play a role in the virus
lifecycle. This can be done using siRNAs.
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As part of this project, a summary of genes identified by whole genome RNAi
screening studies as being implicated in virus lifecycles was obtained by reviewing
the current literature. Within these screens, hits were recognized as genes that were
either up-regulated or down-regulated in response to infection with the virus used in
the study. The viruses were quantified in a number of ways as described in the
introduction to this thesis. Results from these screens showed that a gene that was
commonly identified as a hit was alpha coatamer protein (COPA). This gene was
identified across 8 separate studies using 4 different viruses; influenza A, West Nile
virus, Dengue virus and Hepatitis C virus. The identification of COPA as being
important for replication across a diverse range of viruses suggests that it may be an
important protein for many viruses including the highly pathogenic avian influenza
A/chicken/Vietnam/008/2004 H5N1.
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In order to test this hypothesis we must first determine which cell line can not only
be transfected with siRNAs but will also support both the growth of
A/PuertoRico/8/34 (PR8wt) and A/chicken/Vietnam/008/2004 H5N1 viruses.
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To determine the ability of HeLa, Hep2, U373 and A549 cell lines to support the
growth of influenza A viruses A/PuertoRico/8/34 (PR8wt) and
A/chicken/Vietnam/008/2004 H5N1 virus growth in these cell lines was measured
using tissue culture infectious dose 50s (TCID50). Firstly, HeLa, Hep-2, A549 and
U373 cells were infected with 0.3 MOI of A/PuertoRico/8/34 H1N1 PR8 or 0.1
MOI of A/chicken/Vietnam/008/2004 H5N1 viruses for 24 h. These cells lines were
chosen for a number of reasons including their use in previously published genome-
wide RNAi screens of host-virus interactions, ability to grow well in the laboratory,
as well as their biological relevance to influenza infection; for example A549 is a
lung epithelial cell line. Supernatants from these cells were then serially diluted and
incubated with MDCK cells (H1N1) or Vero cells (H5N1) for 5 days.  At the end of
this time cells were scored for the absence or presence of cytopathic effect (CPE).
TCID50 (see materials and methods) results showed that all four cell lines were able
to support the growth of both viruses. H1N1 PR8 virus titre was highest in HeLa
cells (7.25 TCID50/mL), followed by A549 cells (5.5 TCID50/mL), Hep2 cells (2.25
TCID50/mL) and finally U373 cells (1.75 TCID50/mL). The same pattern was
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observed for H5N1 avian influenza with titres of 6.25 TCID50/mL for A549, 7.5
TCID50/mL for HeLa cells, 5 TCID50/mL for Hep2 cells and 2.25 TCID50/mL for
U373. This experiment was repeated three times with each experiment containing
three internal replicates for each sample group. Figures are from representative
experiments. These results suggest that HeLa cells were most suitable for further
studies of COPA function in the context of avian influenza virus infection if they
could be shown to also support transfection with siRNAs (Figure 3.1).
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Figure 3.1 A/PuertoRico/8/34 H1N1 PR8 and A/chicken/Vietnam/008/2004
H5N1 virus titres in A549, HeLa, Hep2 and U373 cells. a. TCID50 of PR8 H1N1
virus. b. TCID50 of A/Vietnam H5N1 virus. Virus titre was measured by TCID50
five days post infection.  n = 3. Error bars indicate standard deviation of the mean.
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To investigate host genes and proteins with important roles in the host-avian
influenza virus interaction, it was important to establish a system where host factors
expression levels could be influenced by RNA interference in a cell type that
supports virus replication. This study began by investigating a cell line that was
able to be efficiently transfected with short interfering (si) RNAs. The transfection
efficiencies of a number of cell lines were measured using fluorescence microscopy
and flow cytometry. A549, HeLa, Hep2 and U373 cells were each transfected with
siGLO Red, a fluorescently labeled siRNA that allows us to visualise siRNAs in
vitro, using Lipofectamine 2000 transfection reagent (Figure 3.2c). Flow cytometry
was used to determine the number of transfected cells and how well these cells were
transfected. Measurements were then presented as % cells transfected and mean
fluorescence for each of the cell lines. This experiment was performed once with
each treatment group  having three replicates. Each of these cell lines was able to be
transfected. HeLa cells were found to be the most easily transfected with 80% of
cells being transfected, followed by 60% in Hep2 cells, 37% in A549 cells and
finally 32% in U373 cells (Figure 3.2a). Mean fluorescence of HeLa, Hep2, A549
and U373 cells were measured at 15, 12, 7 and 5 (AU) respectively (Figure 3.2b)
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Figure 3.2 Determination of transfection efficiency in A549, HeLa, Hep2 and
U373 cell lines. A) Graph of % cells transfected with siGLO Red 24 h post
transfection.  B) Graph of mean fluorescence of cells transfected with siGLO Red
24h post transfection. C) Photographs show cell lines transfected with siGLO RED
siRNAs at 24 h post transfection. n=3. Scale bar 50μm.
A549               U373                 Hep2                 HeLa
BF
siGLO
C.
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Having established that HeLa cells can be transfected with siRNAs, individual
siRNAs were designed against COPA using Dharmacon’s siDesign centre®
(http://www.dharmacon.com/ccg/designcenter). This online algorithm allows
siRNAs to be designed to incorporate a certain C/G content that the user can
choose. The user is then given the choice of the region within which they desire
their siRNAs to be designed, The 5’ untranslated region (5’UTR), the open reading
frame (ORF) or the 3’ untranslated region (3’UTR), and finally a blast search is
performed to ensure no sequence homology to other genes within the target
organism. In this case, the 3 siRNAs were designed within the ORF, at the
beginning, middle and end of the ORF, using the recommended G/C content; a
minimum and maximum G/C percentage of 30% and 64% respectively. To
determine the effectiveness of the individual COPA siRNAs on silencing COPA
gene expression in HeLa cells, 4e4 HeLa cells/well were transfected individually
with 40 pmol of 3 individual siRNAs targeting COPA in 100μL of media
containing 2μL of L2000 (Figure 3.3).In addition, as a comparison, these siRNAs
were also tested using Hep2 and A549 cells (cells that have previously been used in
screens). Control cells were media treated alone. Changes in the expression of
COPA mRNA levels were measured using QRT-PCR. This experiment was
repeated three times with each experiment containing internal replicates. Figures are
representative of all experiments. At 24 h post transfection, no significant difference
was seen between the media only control and any of the three individual siRNAs in
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the A549 cells. Significant differences were seen between the control and siRNA1
and siRNA3 in Hep2 cells with p values of 0.006874 and 0.000286 respectively.
Significant difference was seen in HeLa cells only for siRNA 3 with a p value of
7.80629E-05 aalthough this was a significant increase and therefore not desirable
(Figure 3.4).
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Figure 3.3 Binding sites of COPA siRNAs synthesised using T7 RNA
polymerase kit within the Open Reading Frame (ORF) of COPA. Individual
siRNA sequences are highlighted.


















				
			














		








- 102 -
- 103 -
Figure 3.4 COPA expression in individual COPA siRNA treated cell lines. a.
COPA expression in COPA siRNA treated A549 cells 48h post transfection.
COPA1 p=0.069124, COPA 2 = 0.629152, COPA 3 = 0.086215. b. COPA
expression in COPA siRNA treated Hep2 cells 48h post transfection. COPA1
p=0.006874 COPA 2 = 0.098673, COPA 3 = 0.000286 c. COPA expression in
COPA siRNA treated HeLa cells 48h post transfection. . COPA1 p=0.020151446,
COPA 2 = 0.0408049 COPA 3 = 7.80629E-05. n= 3, * = significant
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As an alternative to the individually designed and synthesized COPA siRNAs,
smartpool siRNAs, which is a group of 4 individual siRNAs targeting COPA that
are pooled for use as a single siRNA product, were used to silence COPA in HeLa
cells. To determine the effectiveness of the commercially purchased COPA
smartpool siRNAs on silencing COPA gene expression, HeLa cells were transfected
with 40 pmol of COPA smartpool siRNAs using Lipofectamine 2000 transfection
reagent. COPA expression was then measured 24, 48, and 72 h post transfection
using QRT-PCR and compared with COPA expression in untransfected cells whose
expression was normalised to equal 1. This experiment was repeated three times
with each experiment containing three internal replicates. Figures are representative
of three repeated experiments. There was no significant difference between the
COPA siRNA treated cells and the untreated control cells or the non-targeting
siRNAs which are siRNAs that are scrambled sequences lacking homology to any
human gene, 24 h post transfection.  At 72 h post transfection, we saw significant
knockdown with the expression of COPA in the COPA siRNA treated cells was
approximately 65 % lower than the expression of COPA (p = 0.003688) in both the
control and the non-targeting siRNA treated groups. This level of knockdown is the
level that is expected according to the manufacturer and is typical of the timeframe
for knockdown that we see in similar experiments and is an improvement on the
results seen using the individual siRNAs. Once an acceptable level of knockdown
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was shown we were able to progress to our COPA knockdown experiments using
HeLa.
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Figure 3.4 COPA expression in COPA smartpool siRNA treated HeLa cells. a.
COPA expression in Control, COPA smartpool siRNA and NT#2 cells 48h post
transfection, COPA p = 0.0.630896, NT#1 p = 0.003041. b. COPA expression in
Control, COPA smartpool siRNA and NT#2 cells 72h post transfection, COPA p =
0.003688, NT#1 p = 0.891677 n= 3, * = significant.
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3.7 Viability of COPA siRNA treated HeLa cells
To ensure the COPA siRNAs were not having a toxic effect on the HeLa cells,
HeLa cells were transfected with COPA smartpool siRNAs and then checked for
viability using 4’, 6-diamidino-2-phenylindole (DAPI) stain 48 h post transfection.
DAPI is a fluorescent stain that binds strongly to A-T rich regions in the DNA. It
can pass through the membrane of intact cells, allowing the staining of both live and
fixed cells. Although DAPI staining cannot be used to directly measure cell
viability, in this case it was used to count adherent cells after dead cells had been
removed from wells via multiple PBSA washes. Untreated cells and cells treated
with a non- targeting siRNAs were included as negative controls and a polo-like
kinase (PLK) siRNA was included as a death control. PLK is an important regulator
of the cell cycle which is involved in the formation of and the changes in the mitotic
spindle and in the activation of CDK/cyclin complexes during the M phase of the
cell cycle. PLK inhibition induces apoptosis. Cell viability was determined by
counting the number of stained nuclei to determine the number of viable cells by
counting adherent cells after dead cells had been removed from wells via multiple
PBSA washes. This experiment was repeated three times with each experiment
containing three internal replicates. Figures are representative of three repeated
experiments. There was no significant difference in viability observed between the
COPA siRNA treated cells (p= 0.885386) and the control groups L2000 alone (p=
0.667581) and NT#1 (p= 0.741801). Significant cell death was observed in the PLK
death control group (p= 0.001226).
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Figure 3.6 Viability of COPA siRNA treated HeLa cells 24h post transfection.
A) DAPI stained HeLa cells 24 h post transfection  a. Media alone, b. L2000 alone,
c. COPA siRNA, d. NT#1 siRNA, e. PLK death control siRNA. B) Graph of mean
cell number for each treatment group 24 h post transfection. There was no
significant difference seen for COPA, L2000 or NT#1 with p values of 0.89, 0.67
and 0.74 respectively). Significant cell death was seen in the cell death group with a
p vale of 0.0012. n=3. Scale bar 200μm.
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To determine the effect that virus infection would have on the expression of COPA
in influenza A infected HeLa cells, HeLa cells were treated with either poly(C)
(polycytidylic acid) or poly(I:C) (polyinosinic:polycytidylic acid), single stranded
and double stranded RNA virus mimetics, respectively. Virus mimetics were used
in place of viruses. The expression of COPA in poly(I:C) and poly(C) treated cells
was measured 3, 6 and 24 h post transfection using QRT-PCR. This experiment was
performed once, with three internal replicates. At 3 h post infection, there was no
significant change in COPA expression levels in any of the treatment groups
compared to the control, which were untreated cells. At 6 h post infection there was
no significant increase in COPA expression in any of treatment groups compared to
the control. At 24 h post transfection there was significant differences between the
control group and both Poly I:C + L2000 and Poly I:C with p-values of
0.091380503 and 0.091380503 respectively. At 24 h post transfection the average
fold change for the control, poly (I:C) with L2000, poly(I:C) alone and poly(C) with
L2000 treatment groups was 2040, 32, 25 and 12 respectively (figure3.7).
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Figure 3.7 COPA expression in Poly I:C, Poly C and Loxoribine treated HeLa
cells. No significant difference was observed at either 3 or 6 h post transfection. At
24 h post transfection average fold changes for the control, poly(I:C) with L2000,
poly(I:C) alone and poly(C) with L2000 treatment groups was 2040, 32, 25 and 12
respectively with significant differences seen between the control and Poly
I:C+L2000 and Poly C +L2000. n=3
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In addition to the RNA virus mimetics, to determine the effect of influenza A
infection on the expression of COPA in HeLa cells, HeLa cells were infected with
influenza A H1N1 PR8 virus at a concentration of 1:100 of the 2 × E8 PFU stock
virus. COPA expression in virus infected vs. unstimulated cells was then measured
by QRT-PCR. The expression of COPA in unstimulated HeLa cells was normalized
to equal 1 and the expression of COPA in virus-treated cells compared directly to
this. This experiment was performed once with three internal replicates. The
expression of COPA was not significantly different in influenza A H1N1 PR8
infected HeLa cells compared to uninfected HeLa cells 24 h post infection (p =
0.280587) (figure 3.8).
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Figure 3.8 COPA expression in untreated vs. PR8 infected HeLa cells 24h post
infection. HeLa cells infected with A/PuertoRico/8/34 (PR8wt) virus at a
concentration of 1:100. p = 0.280587 n = 3, * = significant
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To determine the effect of silencing COPA expression in HeLa cells on the growth
of avian influenza A H5N1 virus, viral titre were measured by a TCID50 assay in
Vero cells using supernatants taken from H5N1 infected HeLa cells which were
either otherwise untreated or treated prior to infection with COPA smartpool
siRNAs or NT#1 siRNAs. No significant difference in viral titre was observed after
a 5 day incubation period for either of the treatment groups. Viral titre was
measured as 6.75 TCID50/mL in the control cells and 7.5 TCID50/mL with a p value
of 0.249521 in the COPA treated cells and 7.33 with a p value of 0.249521
in the NT#1 treated cells. This experiment was performed once with three
replicates for each treatment.
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Figure 3.9 Effect of COPA knockdown using COPA smartpool siRNAs on viral
titre in HeLa cells. TCID50s for NT#1 siRNA and COPA siRNA HeLa cells
infected with H5N1 showed no significant difference when compared with control
cells, with p values of 0.249521 and 0.249521 respectively. n=3.
- 116 -
		?:51/4++>68+99/54/4 !		/4,+):+*)+229.659:
/4,+):/54
Following the COPA work, additional host gene candidates were identified by
measuring the expression of a subset of  cytokines in response to infection with
A/chicken/Vietnam/008/2004 H5N1 using human α, β interferon response QRT-
PCR arrays. Before this response was measured, experiments were performed on a
smaller scale using a more biologically relevant cell line in order to more accurately
gauge the natural response to influenza A using A/PuertoRico/8/34 (PR8wt).
Cytokines were chosen based on their known involvement in the cytokine storm
response characteristic of infection with highly pathogenic avian influenza (Chan,
Cheung et al. 2005). To determine the effect of influenza A infection on the
expression of a number of cytokines and the potential role of COPA in the
induction of host cytokine responses, the expression of a number of cytokines in
HeLa cells were measured by QRT-PCR. To do this, the biologically relevant A549
cell line was infected with varying doses of H1N1 PR8 virus (see materials and
methods) and cytokine expression measured 6 h post infection in order to gain an
understanding of the initial response to influenza infection.
CXCL10 (Figure 3.10a) expression was significantly increased only by 10-5 virus
dose 6 h post-infection (p = 0.009286). None of the other cytokines measured
showed significant differences at any virus dose.
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Figure 3.10 Cytokine expression in PR8 H1N1 infected A549 cells 6h post
infection. a CXCL10 expression in PR8 H1N1 infected A549. Cells infected with
virus at a concentration of 10-3, 10-4, and 10-5, 10-3 p = 0.033637, 10-4 p = 0.03455,
10-5 p = 0.009286 b. ILIB expression in PR8 H1N1 infected A549 cells. Cells
infected with virus at a concentration of 10-3, 10-4, and 10-5, 10-3 p = 0.715454, 10-4
p = 0.297843, 10-5 p = 0.039664 c. IL6 expression in PR8 H1N1 infected A549
cells. Cells infected with virus at a concentration of 10-3, 10-4, and 10-5, 10-3 p =
0.034848, 10-4 p = 0.419176, 10-5 p = 0.718887 d. CCL5 expression in PR8 H1N1
infected A549 cells. Cells infected with virus at a concentration of 10-3, 10-4, and
10-5, 10-3 p = 0.108609, 10-4 p = 0.920441, 10-5 p = 0.754713 e. CCL2 expression in
PR8 H1N1 infected A549 cells. Cells infected with virus at a concentration of 10-3,
10-4, and 10-5 . 10-3 p = 0.010793, 10-4 p = 0.164789, 10-5 p = undetermined f. TNF
expression in PR8 H1N1 infected A549 cells. Cells infected with virus at a
concentration of 10-3, 10-4, and 10-5 . 10-3 p = 0.75864, 10-4 p = 0.260515, 10-5 p =
0.033559 n = 3, * = significant
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Following this experiment to measure the expression of a small group of cytokines
known to be involved in cytokine storm in response to infection with
A/PuertoRico/8/34 (PR8wt) larger scale work was begun. This work was continued
with HeLa cells to allow for future work that may be performed using HeLas
involving siRNAs. In order to determine the effect of influenza A
A/chicken/Vietnam/008/2004 H5N1 infection on the expression of a larger number
of cytokines, the expression of 84 cytokines as well as a number of house-keeping
and control genes expressed in H5N1 virus infected HeLa cells was determined
using human α,β interferon response QRT-PCR arrays. These arrays are 96 well
plates that contain lyophilized primers to which we add cDNA from infected HeLa
cells. Due to the expense of these arrays, this experiment was performed once. We
hypothesise that there will be a number of these cytokines which will disregulated
in HeLa cells in response to infection with HPAI. Expression was measured at both
6 h and 24 h post-infection, time points chosen due to time points used in the
previous small scale optimisation experiment and due to the time taken for adequate
virus replication to occur in cells. Array data was presented 2 ways. The first as a
summary of over-expressed genes at both 6 and 24 h post infection (Table 3.2). And
second, array data was presented by separating data into a number of subgroups.
Within the ligands and receptors subgroup (Figure 3.11a) interferon alpha 2
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(IFNA2) was most highly upregulated at both 6 h and 24 h post infection showing a
24- and 94-fold induction respectively, the second most highly upregulated at both
6 and 24 h was interferon beta 1 (IFNB1), which showed a 8.6- and 63.5-fold
increases respectively. Within the interferon responsive genes with IFN-responsive
elements subgroup (Figure 3.11 b), neuregulin 1 (NRG1) showed the highest
upregulation at 24h post infection with a 61.2 fold increase, followed closely by
inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2) with a 10.5 and 61.9 fold
increases at 6 and 24 h post infection respectively. These genes were also the most
highly upregulated genes represented within the genes associated with HCV-
induced interferon response subgroup (3.11 c). Within the signaling molecules
subgroup, interferon regulatory factor 7 (IRF7) and interferon regulatory factor 9
(IRF9) were the most highly upregulated genes. IRF9 showed 2.7 and 7.5 fold
increases at 6 and 24 h respectively, whilst IRF7 showed 1.9 and 7.5 fold increases
at 6 and 24 h respectively. Figure 3.7.2 shows genes associated with intrinsic
interferon response. Within this subgroup of cytokines, there were 6 categories,
signal transduction (Figure 3.12 a), apoptosis, (Figure 3.12 b), stress response
(Figure 3.12 c), transcriptional regulation (Figure 3.12d), cell growth (Figure 3.12
e), and others (Figure 3.12 f). Within the signal transduction cytokines significant
fold increases were observed at 24 h post infection SH2 domain containing 1A
(SH2D1A) showed a fold increase of 31.2 and SAM domain, SH3 domain and
nuclear localization signals 1 (SAMSN1) showed a 38.6 fold increase. Within the
apoptosis cytokines, significantly increased fold changes were observed again only
at 24 h post infection and only for BCL2-associated athanogene 3 (BAG3) which
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showed a 9.6 fold increase. Within the stress response cytokines, a significant
increase in fold was observed for a single gene, heat shock 70 kDa protein 1-like
(HSPA1L) at 24 h post infection with a 24.2 fold increase. Within the
transcriptional regulation genes, a significant fold increase of 9.7 was observed for
the gene interferon regulatory factor 5 (IRF5) 24 h post infection. Within the cell
growth genes significant fold increases were seen at 24h post infection for
interferon induced transmembrane protein 1 (IFITM1) with a fold increase of 6,
cyclin-dependent kinase inhibitor 1B, CDKN1B) with a fold increase of 7.7 and
vascular endothelial growth factor A (VEGFA) with a fold increase of 9.6. Within
the other cytokines within this subgroup, the expression of only two genes were
significantly increased at 6 h post infection. Major histocompatibility complex,
class II, DO alpha (HLA-DOA) with a fold increase of 11 and solute carrier family
1 (glial high affinity glutamate transporter), member 2 SLC1A2) with a fold
increase of 71.9. At 24 h post infection there were a number of genes with
significant fold increases, HLA-C with 80.9 fold increase, HLA-DOA with 38.4
fold increase, HLA-DOA with 24.2 fold increase, IFI27 with 15.3 fold increase,
MX2 with 61.7 and SLC1A2 with 418.6 fold increase.
Overall, SLC1A2 was the most highly upregulated across all 84 cytokines
measured. SLC1A2 was upregulated significantly more than any other cytokine in
response to H5N1 infection with a fold increase of 71.5. These results provide us
with potential targets for new antiviral therapeutics, as candidates which were
upregulated in response to infection with HPAI are potentially playing an important
role in the virus lifecycle and therefore silencing these may have an inhibitory effect
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on the growth of HPAI. Investigating the expression of these cytokines during
infection whilst simultaneously knocking down other host factors known to be
important during virus infection such as COPA may provide further insights into
the role of these host factors.
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Table 3.1 Cytokine expression in response to infection with A/Vietnam H5N1
virus at 6h and 24h post infection. a. Fold regulation 6 h post infection. b. Fold
regulation 24 h post infection.
a. 6 h post infection
CXCL10 8.5845
HLA-DOA 11.0117
IFNA2 26.4342
IFNA4 5.3511
IFNB1 8.6801
ISG20 4.1768
ITIH2 10.5611
MX2 8.4613
OAS2 6.7724
SAMSN1 4.2653
SLC1A2 71.8568
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b. 24 h post infection
ARL5B 9.6462
BAG3 9.5903
CDKN1B 7.6735
CXCL10 31.2038
GCH1 6.0809
HLA-C 29.5294
HLA-DOA 80.9187
HLA-DQA1 38.3813
HSPA1L 24.2306
IFI27 15.2693
IFIT1 4.8136
IFITM1 6.0719
IFNA1 9.6206
IFNA2 97.0941
IFNA4 24.6581
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IFNB1 63.5267
IRF5 9.6527
IRF7 7.5866
IRF9 7.5971
ISG20 9.6166
ITIH2 61.9067
MAL 5.6589
MX1 12.0547
MX2 61.679
NRG1 61.2612
OAS2 62.3925
SAMSN1 38.5988
SH2D1A 31.217
SHB 9.6731
SLC1A2 418.5647
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TNFSF10 12.1434
TRAF3 6.0786
VEGFA 9.6006
HGDC 38.6664
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Figure 3.11 Cytokine induction in HeLa cells in response to A/Vietnam H5N1
infection. Fold changes in Ligands and Receptors, interferon responsive genes with
IFN responsive elements, Signaling molecules and Genes Associates with HCV-
Induced Interferon Resistance at 6 and 24 h post infection.
- 128 -
Figure 3.12 Cytokine induction in HeLa cells in response to A/Vietnam H5N1
infection; Genes Associated with Intrinsic Interferon Response. Fold change in
Signal transduction genes, apoptosis genes, stress response genes, transcriptional
regulation genes, cell growth genes and other genes at 6 and 24 h post transfection.
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Results chapter 2.
The development and optimisation of methods to visualize
the host-avian influenza virus interaction.
	4:85*;):/54
In the previous chapter I described the interaction of avian influenza virus with a
particular host molecule; COPA. Studies of host-virus interactions are wide
ranging; from small scale in vitro experiments in tissue culture to large scale in
vitro assays such as whole genome siRNA screens and large scale in vivo
pathogenesis studies using animal models. Each of these studies would benefit
enormously from a method to visualise, track and quantitate virus in real time.   One
potential method to achieve this goal is the development of a reporter virus
expressing green fluorescent protein (GFP). There are a number of benefits of
using a GFP reporter virus as opposed to the other available readout methods,
including the reduction in the need for the use of secondary reagents such as
antibodies in order to visualise virus both in vitro and in vivo. Not only does this
have the potential to significantly reduce reagent costs within the laboratory, it also
allows for practical applications such as the real time and continuous imaging of
cell lines and infected animals throughout an experiment, unlike antibody staining
methods which require cells to be fixed and then antibody stained before the virus
can be visualized and quantified. A GFP reporter virus would be of particular use
in in vivo studies where the dynamics of influenza virus infection and the cell types
that are infected are not well understood (Manicassamy, Manicassamy et al. 2010).
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In particular the manufacture of a GFP-expressing H5N1 virus would significantly
benefit the attempts to better understand the host pathogen interactions in animal
models such as poultry, ducks and ferrets.  A GFP reporter virus would better allow
us to track the migration of the virus through the host as the virus replicates and the
infection spreads. Other technologies utilized as readout methods for whole genome
screens include measuring luciferase activity as seen in a studies by Hao and
colleagues in 2008 involving an RNAi screen to identify host genes important for
influenza virus replication and a study by Konig and colleagues in 2009 looking at
the human host factors required for influenza virus replication (Hao, Sakurai et al.
2008), (Konig, Stertz et al. 2010).  Other studies such as the one by Brass and
colleagues in 2009 have used HA immunostain to investigate the host proteins
involved in H1N1 and West Nile virus replication by Brass et al., in 2009, or, as in
the study by Shapira and colleagues in 2009, have measured infectious virus or IFN
production to reveal the pathways involved in influenza infection (Brass, Huang et
al. 2009), (Shapira et al., in 2009).  Finally, in 2010 a study by Karlas and
colleagues involving infectious virus identified host factors crucial for influenza
virus replication using a 293T cell reporter system and NP immunostain (Karlas,
Machuy et al. 2010).
Recently a group headed by Adolfo García-Sastre at Mt. Sinai School of Medicine
in New York developed a recombinant GFP reporter influenza A H1N1 virus by
inserting a GFP fragment construct into the non-structural (NS) gene (NS1-GFP
virus) (Manicassamy, Manicassamy et al. 2010).  The influenza A NS gene segment
encodes both NS1 and NS2 (Nuclear export protein (NEP)).  NS1 is produced from
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unspliced mRNA and NEP produced from the spliced mRNA.  The Mt Sinai Group
modified the NS gene segment by expressing NS1-GFP and NEP as a single
polyprotein with a 19 amino acid porcine teschovirus-1 (PTV-1) 2A autoproteolytic
cleavage site between them.  This cleavage site allowed the group to produce a gene
where the NEP is released from the NS1-GFP protein during translation, so two
separate proteins are generated.  To avoid splicing of the acceptor site, two silent
mutations were also added (Manicassamy, Manicassamy et al. 2010) (see figure
4.10).  Once this GFP containing NS gene was constructed, the virus was rescued
using the 8-plasmid reverse genetics system. Using this method they were able to
generate a functional influenza A H1N1 virus that was able to retain the GFP
through passage and remain virulent, though it was attenuated when compared to its
wild-type counterpart (Manicassamy, Manicassamy et al. 2010). The presence of
the GFP segment in the NS gene alters the size of the NS segment from
approximately 0.89 kb to almost twice its size at 1.89 kb. Inserting a fragment of
this size into the NS gene was shown to affect the virus replication cycle in vitro
using MDCK cells when compared to the growth of the wild-type H1N1 virus. The
group was able to show that the GFP reporter virus was able to undergo multicycle
replication in MDCK cells however it reached ≈100-fold lower titres than the wild-
type virus. Based on the survival data of the infected animals used by this group,
they were able to demonstrate that whilst still pathogenic in mice, this virus was
attenuated compared with the wild type virus giving a lethal dose50 (LD50) value
which was approximately 100-fold higher that of the wild type H1N1 virus
(Manicassamy, Manicassamy et al. 2010). Despite the reductions in viral titre and
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virulence compared to the wild-type virus, this kind of GFP reporter virus, which
stably expresses GFP through replication was still able to cause lethality in mice
and is particularly useful in in vivo studies which look at the impact of virus
inhibiting strategies such as the use of anti-viral drugs and siRNA host factor
silencing (i.e. COPA).
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As yet, there are no published reports of other groups manufacturing this virus, or
any other work describing a NS GFP reporter influenza A virus in in vitro or in vivo
studies. It was important in my work to establish the feasibility of manufacturing
this virus using the 8-plasmid reverse genetics system in order to determine the
likelihood of using this method to develop a GFP expressing highly pathogenic
avian influenza A H5N1 virus at biological safety level 3 (BSL3). Inserting a
fragment of this size into an influenza A virus gene is problematic.  Influenza virus
is difficult to rescue if we insert foreign gene segments into any of the 8 influenza A
gene segments, especially as the insert sizes increase (Manicassamy, Manicassamy
et al. 2010). In addition, viruses that contain inserts are likely to be less virulent if
they are able to be rescued. The GFP reporter H1N1 virus rescued by Manicassamy
et al is an example of this.
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The 8-plasmid reverse genetics system used in the attempt to rescue a GFP reporter
influenza A H1N1 virus was developed by Hoffman et al in 2000 at the Department
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of Virology and Molecular Biology at St.  Judes Children’s Research Hospital in
Memphis, Tennessee.  This 8-plasmid based system works by inserting viral genes
between the RNA polymerase 1 (pol 1) promoter and terminator sequences within
PHW2000 plasmids.  This system has advantages over previous systems in the fact
that unlike others, this system is more simplified.  This 8-plasmid reverse genetics
system allows the generation of influenza A virus entirely from plasmids, which
means there is no requirement for infection with a helper virus.  This system allows
the manipulation of each individual gene segment, providing potentially endless
possibilities for alterations and additions as well as the potential combination of any
HA, NA subtype combination (Hoffman et al., 2000).
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The development of a GFP expressing influenza A virus using the 8-plasmid
reverse genetics system involves the insertion of a GFP gene fragment into the NS
gene of influenza A, which would then be used to rescue a complete influenza A
virus.
Here we constructed a functionally active NS1 and NS2(NEP) which was expressed
as a single polyprotein containing a 2A autoproteolytic cleavage site which during
translation allowed the NS1 containing the GFP insert to be separated from the
NEP.
The NS-GFP fragment was excised from the plasmid in which it arrived and ligated
into a PHW2000 plasmid which is the plasmid used in the reverse genetics system
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that would be used to later rescue an NS-GFP expressing influenza A H1N1 virus.
The NS-GFP segment was cut from the vector using NS-BSMBI primers providing
the correct sticky ends for ligation into the PHW2000 plasmid.   The resulting
fragment was digested with BSMBI enzyme releasing fragments of expected size of
1.85 kb and 0.98 kb as well as an unexpected band at 0.45 kb.  The 1.85 kb band
represented the NS-GFP and was purified to clone into PHW2000.
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Figure 4.1 NS-GPF cut from vector using NS-BSMBI primers
NS-GFP segment was cut from vector using NS-BSMB1 primers. NS in PHW2000
vector used as positive control.
#  "-
1.85kb
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Figure 4.2 BSMB1 enzyme digestion of NS-GFP cut from vector
BSMB1 primers were used to digest the NSGFP cut from the vector. Positive
control was PR8 H1N1 NS segment and the negative control contained no DNA.
# "-  "-
1.85kb
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After ligating the NS-GFP fragment with BSMBI ends into the PHW2000 plasmid,
the plasmid was sequenced to confirm the sequence identity of the NS-GFP
fragment.  This sequence was found to contain the intact NS1 and NS2 regions
along with the GFP segment, a GSGG linker and the introduced (PTV-1) 2A
autoproteolytic cleavage site.   The sequencing identified two single base pair
changes within the NS-GFP in PHW2000 plasmid, though neither of these
mutations produced a change in the amino acid encoded and as such were classified
silent mutations (Figure 4.10).
- 138 -
Figure 4.3 NS-GFP in PHW2000 sequencing. NS-GFP in PHW2000 was
sequenced using BigDye terminator reagent. Sequence was found to be identical to
that of the provided plasmid, with only two single base pair changes which did not
affect the amino acid produced.
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4.2.3 Functional NS- GFP in PHW2000 plasmid – imaging
Following the sequencing the plasmid was checked for functionality.   To determine
whether the NS-GFP-PHW2000 plasmid (Figure 4.5a) was functional, human
embryonic kidney 293T (HEK293T) cells were transfected with the NS-GFP-
PHW2000 plasmid using Lipofectamine 2000 reagent.   These cells were chosen as
they are readily transfectable.   Images of the transfected cells were then obtained
using fluorescent microscopy 24 h post transfection to check for the expression of
GFP.  The transfected Hek293T cells were shown to be fluorescing demonstrating
that they were expressing the GFP protein. This indicates that the NS-GFP
PHW2000 plasmid created was functional (Figure 4.5b).
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Figure 4.5. Functional NS-GFP in PHW2000 plasmid
a. NS-GFP segment with BSMB1 ends ligated into PHW2000 plasmid to create a
functional NS-GFP plasmid. b. Images of functional NS-GFP plasmid fluorescing
inside transfected ek293T cells 24h post transfection. Magnification x 200.
NS-GFP BSMBIBSMBI


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Once it was established that the NS-GFP PHW2000 plasmid was functional, rescue
of a GFP expressing influenza A/PeurtoRico/8 H1N1 virus was attempted using the
8-plasmid reverse genetics system.  A co-culture of MDCK and HEK293T cells
were transfected with the 8 plasmids using FuGENE transfection reagent and then
after a 24 h incubation period, trypsin was added to the cell media in order to allow
the rescued virus to be cleaved and released from the cells.  Fugene was the
standard transfection reagent used for this reverse genetics procedure however as a
troubleshooting approach, Lipofectamine 2000 transfection reagent was also used,
following the manufacturers guidelines.  Trypsin is required to cleave the surface
protein Haemaglutinin (HA) which allows release of virus from the cell surface.  A
wild-type NS virus control and a negative (- NS) control were included alongside
the NS-GFP virus for comparison.  The Negative control (-NS) virus was created by
transfecting each of the 8 individual gene segments that make up an influenza A
virus except the NS segment.  Influenza requires all 8 gene segments in order to
generate a complete and functional virus, without NS the virus cannot be rescued.
Transfected cells were examined for the presence of rescued virus by fluorescence
microscopy to detect GFP 24 h post transfection (before the addition of trypsin)
(Figure 4.6a), again at 24 h post-trypsin (Figure 4.6b) and finally at 48 h post-
trypsin (Figure 4.6c).  There was a limited amount of fluorescence present at 24h
post transfection (before the addition of trypsin) in the NS-GFP transfected cells
due to the presence of the functional NS-GFP plasmid (Figure 4.6a). No
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fluorescence was seen in either the wild type virus or negative control virus groups
at this time point.  However, no increase in the amount of GFP fluorescence was
observed after the addition of the virus cleaving trypsin at either 24 h or 48 h post
trypsin in the NS-GFP transfected cells, nor was any fluorescence seen in either the
wild type virus or negative control virus groups at these time points.
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Figure 4.6. NS-GFP H1N1 virus could not be rescued using 8-plasmid reverse
genetics system with the PHW2000 NS-GFP plasmid. a. BF and Fluorescent
images of WT, -ive control and NS-GFP treated HeLas prior to adding trypsin.
Observed fluorescence in NS- GFP images is due to presence of the functional NS-
GFP plasmid. b. BF and Fluorescent images of WT, -ive control and NS-GFP
treated HeLa cells 24h after adding trypsin. No observable increase in GFP
fluorescence. c. BF and Fluorescent images of WT, -ive control and NS-GFP
treated HeLa cells 48h after adding trypsin. No observable increase in GFP
fluorescence. Figure is representative of >12 repeat experiments. Magnification x
40
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A Haemagluttination (HA) assay was also performed on supernatants taken from
the three treatment groups 48 h post trypsin to detect the presence of virus.   HA
assays are a method of quantification for viruses which works due to the presence
of proteins within the virus which agglutinate to red blood cells (RBC).   To
perform a HA assay serial dilutions of cell supernatant are combined with chicken
RBCs to detect the presence of virus within the supernatant sample.  If virus is
present, agglutination will occur and the RBCs will form a sheet across the well
which will appear red, if not, the RBCs fall to the bottom of the v-shaped well and
only a red dot will be present in the centre of the well.   Results from HA assays
confirmed that there was no virus present in the cell supernatant of the negative
control or the NS-GFP transfected cells.  Virus was present in the wild-type virus
control group at this time point (Figure 4.6d).  Numerous attempts (>12) at virus
rescue of the NS-GFP H1N1 virus using the 8-plasmid reverse genetics system
yielded like results.   It is common for numerous attempts at virus rescue be
performed before virus is able to be rescued.   Both FuGENE and Lipofectamine
transfection reagents were used to attempt virus rescue, as well as different plasmid
batches.
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Due to the difficulty in rescuing an influenza A virus with the relatively large added
GFP insert, and due to the impact the GFP fragment has on the virulence of the
virus, as seen in the attempts at Mt. Sinai, an alternative method for quantifying
and/or imaging virus infection in vitro may be required.  A number of options are
available; however for imaging the most practical option is to use antibodies to stain
and then image the virus.  To find an alternative method for imaging infected cells
in place of the GFP reporter virus, antibody assay conditions for resulting highly
pathogenic avian influenza A H5N1 infections in HeLa cells were optimized.  This
optimisation involved finding an antibody that would stain both H1N1 and H5N1
viruses in infected HeLa cells and to determine an appropriate antibody
concentration with which to treat the cells to reduce background staining which
would make the virus harder to quantify.
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To find an alternative method for visualizing the host-virus interaction in the
absence of the GFP reporter virus, conditions were optimized to find an antibody
that would stain both H1N1 and H5N1 viruses in infected HeLa cells and to
determine an appropriate antibody concentration.  To find an antibody that would
be appropriate for both virus strains, an antibody against one of the conserved
internal influenza genes was chosen rather than an antibody that stains one of the
genes which expresses a surface protein. Antibody 130, a rabbit-anti antibody
which stains the internal NP protein of influenza A virus was tested at varying
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dilutions ranging from 1:800 to 1:2000. This antibody was provided by the AAHL
histology laboratory and was generated by inoculating rabbits with avian influenza.
A dilution of 1:1200 was found to be suitable for both antibodies when used in
influenza A infected HeLa cells 24 h post infection. The secondary antibody used
for virus (shown in green) was a Goat anti-rabbit conjugated to Alexa 448 used at a
dilution of 1:1200. The secondary antibody used for the Golgi (GM130 shown in
red) was a Goat anti-mouse conjugated to Alexa 568 used at a dilution of 1:1200.
Antibody 130 demonstrated very low background staining in both the control and
the virus treated HeLa cells (Figure 4.7a, b, c).  It was able to stain both H5N1 virus
(Figure 4.7b) and H1N1 virus (Figure 4.7c).  Antibody 127 demonstrated similar
results however the background staining was greater than that of antibody 130
(Figure 4.7d). A greater level of virus staining was seen in the H5N1 virus infected
cells when compared to the H1N1 virus infected and control cells.  Following the
optimisation of a readout method for determining the presence of virus in infected
HeLa cells, experiments to determine the effect of COPA siRNA transfection on the
host cell were performed.
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Figure 4.7. Antibody optimisation for H1N1 and H5N1 in HeLa cells for
confocal microscopy. a. Uninfected HeLa cells treated with a mouse anti NP
antibody at 1:800 dilutions. b. HeLa cells 24 h post infection with Influenza A
H5N1 at a concentration of 1:1000. Treated with mouse-anti NP antibody at a
dilution of 1:800. c. HeLa cells 24 h post infection with Influenza A H1N1 at a
concentration of 1:100. Treated with mouse-anti NP antibody at a dilution of 1800.
n=3. Scale bar 20 μm.
a.
b.
c.
- 148 -
#.++,,+):5, 145)1*5=454 9/!:8'49,+):+*
+')+229
A number of whole genome siRNA screening papers have shown that silencing
COPA inhibits the growth of influenza H1N1 virus in vitro (Brass et al., 2008,
Mehle et al., 2009, Konig et al., 2009, Li et al 2009, Kaarlas et al., 2010).  In order
to better understand the effect of COPA silencing on the organelles associated with
the COPI transport system and to establish whether or not working concentrations
of COPA smartpool siRNAs were toxic in HeLa cells, HeLa cells were imaged
using confocal microscopy by antibody staining with a mouse- anti NP antibody.
The nuclei and Golgi of both untreated and COPA smartpool siRNA treated HeLa
cells were also stained.  There were no negative effects seen in the nuclei of COPA
siRNA treated cells (Figure 4.8b) when compared to the untreated HeLa cells
(Figure 4.8a), however treatment with COPA smartpool siRNAs appeared to cause
dispersion of the Golgi stacks throughout the cytoplasm when compared to the
distinct grouped stacks evident in the untreated HeLa cells. Both the untreated and
the COPA smartpool siRNA treated cells appeared healthy at this time point, with
no differences in the health of the cell other than the differences in the Golgi
evident at this time point.  This is consistent with the DAPI cell viability experiment
results.  No cell death was apparent by microscopy in any of the samples post
transfection at this concentration.
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Figure 4.8. Effect of COPA knockdown on the Golgi in COPA siRNA
transfected HeLa cells.
a. Control HeLa cells 24h post transfection. Nucleus stained with DAPI (Blue
1:400), Golgi stained Red (GM130 1:400) b. COPA siRNA treated HeLa cells 24h
post transfection. Nucleus stained with DAPI (Blue 1:400), Golgi stained Red
(GM130 1:400). Figures representative of n=3 repeats. Scale bar 10μm.
a.
b.
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After determining the effect of treatment with the COPA smartpool siRNAs on the
organelles associated with the COPI vesicular transport system in HeLa cells, the
effect of silencing COPA using siRNAs on the growth of highly pathogenic avian
influenza A H5N1 virus was observed using confocal microscopy. HeLa cells were
first treated with either a non-targeting siRNA or a COPA smartpool siRNA and
then infected with influenza A H5N1 virus 48 h post transfection, a time point
which allowed for adequate silencing at time of virus infection. Cells were infected
for 24 h with a MOI of 0.1. A non-siRNA treated, media only control was also
infected with H5N1.  The cells were then antibody stained using the rabbit-anti
antibody #127 to observe the virus growth (Shown in green) within the cells as well
as the nuclei (Blue) and Golgi bodies (Red).  There was no apparent difference in
the appearance of the nuclei of the cells between any of the treatment group (Figure
4.9).  In the infected non –siRNA treated control cells virus was present and
widespread across the cells.  In the COPA smartpool siRNA treated cells virus was
also present, however the distribution of virus amongst the cells appeared to be
influenced by the presence or absence of Golgi bodies within the cell, with more
virus seen in cells with intact Golgi.  Within this treatment group, the COPA
smartpool siRNAs had an effect on the Golgi, whereby in some of the cells Golgi
were apparently completely absent, significantly reduced in number, or dispersed
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across the cell when compared with the control cells.  In the COPA smartpool
siRNA treated cells the amount of virus present in cells with intact Golgi was
greater than that in the cells without Golgi or with reduced or dispersed Golgi
stacks, when compared to the control samples (Figure 4.9).  In the NT#1 treatment
group virus was present and widespread across the cells.  There appears to be some
slight dispersion of the Golgi bodies in this treatment group when compared to the
control, however overall, the Golgi remain intact in this treatment group.  These
results demonstrate that there appears to be a correlation between virus levels and
number of intact Golgi bodies within a cell.
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Figure 4.9. Confocal imaging of A/Vietnam H5N1 virus in untreated vs. COPA
siRNA treated HeLa cells. a. H5N1 infected HeLa control, b. H5N1 HeLa control,
c. H5N1 infected, COPA siRNA treated HeLa cells, d. H5N1 infected COPA
siRNA treated HeLa cells, e. H5N1 infected, NT#1 siRNA treated HeLa cells, f.
H5N1 infected NT#1 siRNA treated HeLa cells. n=3. Scale bar 20 μm.
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Discussion
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Influenza A infection is a global problem which affects not only health but also has
significant economic impact. Current seasonal vaccines and antiviral therapeutics
are not adequate in the face of new emerging zoonotic influenza viruses and new
therapeutic approaches to tackling this problem are required. Current therapies
focus on the creation of antiviral drugs and vaccines against one or more viruses.
One potential area of investigation for novel therapeutics is the idea of targeting the
host rather than the virus. Viruses are obligate pathogens and as such require the use
of a number of host associated proteins and machinery in order to undergo their
replicative lifecycle. Identifying and manipulating these host factors may be a novel
way of inhibiting viral growth. This thesis investigates the role of host factors, in
particular COPA, on the growth of highly pathogenic avian influenza A virus H5N1
in vitro. A number of steps were undertaken in order to complete this study
including work to create a GFP reporter virus which could then be used to visualize
the role of COPA in the host-virus interaction.
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Despite being able to create a functional NS-GFP plasmid, as evidenced by GFP
fluorescence after transfection in Hek293T cells and by sequencing of the NS-GFP
segment to confirm there were no mutations, the GFP reporter virus was not able to
- 155 -
be rescued within the time allowed. This difficulty rescuing was likely due to the
impact of including such a large insert into the influenza NS gene segment. Adding
inserts decreases the stability of the virus and therefore makes it more difficult to
rescue the virus, it can become a trial and error process where the virus is rescued
by chance and repeated rescue attempts are generally necessary in order to rescue a
functional virus containing your insert. This is especially relevant when we consider
reverse genetic experiments involving manipulating the NS gene, one of only two
genes within the influenza genome that undergoes splicing during infection (Varble,
Chua et al. 2010). These genes, more than the other 6 have greater potential for
errors during the formation of an infectious virus particle to the complicated nature
of inserting foreign genetic material into these genes compared with the others. In
this case however, sequencing and imaging results confirmed the construction of a
functional NS-GFP so the potential instability of this gene due to the splicing it
undergoes during infection had no effect.  During reverse genetics reactions, the
virus may also revert back to wild type by ‘spitting out’ the insert. It is possible that
this was the case and that during this process, the NS gene became unstable and
therefore a virus particle was not able to be formed.
Considering the prior creation of a H1N1 virus containing a GFP expressing NS
gene, despite difficulties rescuing, multiple attempts (approximately 10 attempts) at
rescuing this virus were made. These attempts are detailed in the methods section.
A number of variations to the method were included in the attempts to rescue virus
including the use of different transfection reagents and varied incubation times.
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The benefits of developing an influenza A H5N1 reporter virus are great enough to
be worthy of continued efforts. If the low pathogenic H1N1 virus could be
manufactured and characterized the next step would be to produce a functional and
virulent H5N1 reporter virus. This virus would be of great value and would have a
wide range of uses from in vitro assays to in vivo assays to determine virulence and
growth and infection characteristics within the host. One particular application for
a recombinant reporter H5N1 virus would be genome-wide RNAi screening, where
the reporter virus would simplify laboratory work done at containment.  It would
also save researchers the expenses of antibody-based detection methods. The
advantages of using the 8-plasmid system to rescue virus is that we can potentially
make any change or add any insert into any of the 8 influenza A genes. This
provides us with a great resource for investigating the effect of host factor silencing
on the growth of influenza A. In addition to the work we can do with influenza A,
the potential for the types of virus created are endless, especially at containment
laboratories such as AAHL where BSL-2, -3, and -4 are available. For BSL-4
viruses such as Hendra, Nipah, Ebola and SARS, there is a need for therapeutics.
The use of reporter viruses allow us to measure the effects of silencing host factors
on a wide scale using whole genome screening technique, or other techniques such
as whole animal studies or on a smaller scale by measuring virus growth after
silencing individual host genes which have been implicated in virus lifecycles such
as COPA. If a reporter virus was not able to be created we must look to alternative
methods for the readout of whole genome screens and measuring virus growth as
detailed previously. For the assessment of the impact of COPA inhibition on the
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growth of virus titre in vitro, in the absence of a GFP reporter virus, virus can be
imaged and quantitated using antibodies and TCID50 assays respectively.
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COPA was silenced in human cell lines using siRNA technology. This included
work with both individual siRNAs and commercially purchased smartpool siRNAs.
The individual COPA siRNAs gave varying degrees of knockdown with the highest
level seen at 24 h post transfection using the individual COPA1 siRNA. Due to the
limited success in achieving knockdown using these individual COPA siRNAs, I
then moved onto work using commercially available COPA smartpool siRNAs. A
smartpool siRNA is a collection of 4 different siRNAs all targeting the same gene
used in concert to maximize knockdown. Using these siRNAs a greater level of
knockdown was able to be achieved, with approximately 65% - 70% knockdown
seen in HeLa cells 72h post transfection, a level that is guaranteed achievable by the
manufacturer when using these reagents. The greater knockdown was due to the
combined effect of a number of siRNAs against the same gene vs. the effect of only
a single siRNA. The advantage of using commercially purchased smartpool is in
their design which aims to reduce off target effects. It also comes from the fact that
the smartpool siRNA is a collection of different siRNAs each targeting the gene of
interest. A cumulative silencing approach such as this increases the level of
silencing observed, helps to reduce the number of false positive hits and allows us
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to confirm silencing using the individual siRNAs that comprise the smartpool
following an experiment using the smartpool collectively.
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Once it was shown that the siRNAs were able to knock down the COPA gene in
vitro, it was necessary to determine whether the siRNAs were having a toxic effect.
Assays using DAPI staining to assess the number of viable nuclei post transfection
showed that the siRNAs were non-toxic within a 72 hour knockdown period at the
concentration given to the cells. This data was confirmed by comparison to control
and death control treatment groups. These results differ from literature where
COPA has been shown to have a toxic effect. Cureton and colleagues combined
HeLa cells and siRNA duplexes at a final concentration of 5 × 104 cells ml-1 and 25
nM siRNA. At this concentration the COPA smartpool siRNAs killed
approximately 50 % of the cell population, as measured by counting viable nuclei
(Cureton, Burdeinick-Kerr et al. 2012) The disparities in these results are due to
differences in the concentrations of siRNAs used. Using the smartpool siRNAs, an
adequate level of knockdown was able to be achieved at a concentration low
enough so as not to cause cell death. Interestingly, siRNAs targeting the other
proteins in the COPI complex did not cause cell death (Cureton, Burdeinick-Kerr et
al. 2012).
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There were some disparities between the TCID50 viral titre results and the confocal
imaging results as to the effect of COPA knockdown on virus growth within HeLa
cells. Whilst the TCID50 results were unable to demonstrate a reduction in viral
titre in response to treatment with COPA smartpool siRNAs, there was an effect
observed in the cells upon imaging. In the imaged cells there was a mixed
population of cells that had either functional Golgi, or absent Golgi. The imaging
showed that in the COPA smartpool siRNA treated cells there was a relationship
between the presence of functional Golgi in the HeLa cells and the amount of virus
present. In these COPA smartpool siRNA treated cells, there was virus present in
the cells with Golgi which was comparable to the levels seen in the untransfected
control cells and little to no virus present in the cells missing their Golgi when
compared to the untransfected control. The cells that were missing their Golgi were
most likely cells that had been successfully transfected with the siRNAs whilst the
cells with functional Golgi were likely cells that were not transfected. In this case,
this would mean that COPA smartpool siRNA treatment had a direct impact on the
Golgi within the cell and that the presence of Golgi is necessary for virus
replication within the cell. The Golgi body is also known to be important for virus
replication due to its role in the transport of membrane proteins to the cell surface
via the trans-Golgi network (TGN) (Pielak and Chou 2011). If silencing COPA
using siRNAs has an impact on the structure and/or function of the Golgi, as
suggested in the images taken of transfected cells using confocal microscopy (figure
4.8) then we can hypothesise that the virus inhibition seen in COPA silenced cells is
due primarily to the disturbed function of the Golgi complex.
- 160 -
This result is supported by a recent publication by Cureton and colleagues which
investigates the impact of silencing COPA on the growth of Vesicular Stomatis
Virus (VSV) in vitro (Cureton, Burdeinick-Kerr et al. 2012). They discovered that
by disrupting COPA function using RNAi they were able to inhibit an early stage of
VSV replication. They also demonstrate that the use of a chemical Golgi blocker
Brefeldin A (BFA) inhibits VSV gene expression following a short term BFA
treatment (1 h), and also blocks VSV entry following long term BFA treatment
(12h).They propose a mechanism by which prolonged coatomer inactivation
perturbs cellular endocytic transport and thereby indirectly impairs the entry of
VSV. Their results provide an explanation of why the COPI coatomer is regularly
identified in whole genome siRNA screens as a cellular host factor that may be
important for supporting virus infection (Cureton, Burdeinick-Kerr et al. 2012).
Considering the toxic effects of silencing COPA using siRNAs, its potentially
beneficial to consider inhibiting virus through the silencing of other COPI subunits
which were also able to show virus inhibition when silenced despite the reduced
toxic effects (Cureton, Burdeinick-Kerr et al. 2012). The disparity between the
TCID50 results and the imaging results is possibly due to the 5 day culture and the
kinetics of viral replication. Future experimentation would benefit from added time
points to better assess the kinetics of virus growth in response to COPA silencing.
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In the experiment to measure COPA expression in influenza A H1N1 infected cells,
it was found that COPA levels were not significantly reduced during influenza A
infection (figure 3.8), although a trend towards a reduction may be apparent. This
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result is not surprising considering the implications for COPA in the virus lifecycle
as discussed in the screening papers described earlier. It is also supported by the
imaging results which would suggest that COPA knockdown has a significant
impact on the health of the Golgi which appear to be necessary for the virus
lifecycle.
More investigation of the effects of COPA knockdown on the growth of influenza
A H5N1, both in vitro and in vivo are required. The next step is to repeat the COPA
knockdown and H5N1 infection in HeLa cells in order to look more closely at the
interaction of virus with the cell and cellular organelles during infection using
confocal microcopy to gain a better understanding of the impact of silencing COPA
on virus entry into the cell and the ensuing replication. Following this, other
methods of COPI inhibition such as the use a BFA to block Golgi function can be
used to confirm the importance of COPI inhibition for the replication of H5N1 and
the mechanism by which the virus replication is being inhibited. It may also be
useful in eliminating some of the toxicity concerns associated with the use of
siRNAs. If we can demonstrate a definitive role for COPA during influenza A
H5N1 infection, there is the potential to develop a novel antiviral therapeutic
against H5N1 based on this.
?:51/4+9
In addition to COPA, cytokines are another set of host factors which may be
implicated in virus lifecycles. Before studying the cytokine response to H5N1, the
expression of a number of cytokines involved in cytokine storm were measured
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using influenza A H1N1 virus. Of all of the cytokines measured in A549 cells
during an influenza A H1N1 (PR8) virus infection, the expression of CXCL10
(Figure 3.12a) was most affected with increases measured for all virus doses.
CXCL10 encodes a chemokine of the CXC subfamily and ligand for the receptor
CXCR3. Binding of this protein to CXCR3 results in multiple effects, including
stimulation of monocytes, natural killer and T-cell migration, and modulation of
adhesion molecule expression. Knockdown of this gene may have a significant
impact on the immune response to infection with influenza A virus and may provide
a potential candidate for further investigation into novel therapeutics. Following
this, a mini screen was performed to identify cytokines up or down regulated in
response to H5N1 infection. The mini screen QRT-PCR arrays used in this project
to measure the expression of 84 human α,β response genes and cytokines in
response to infection with H5N1 virus highlighted a number of cytokines which are
up-regulated during influenza A H5N1infection at both 6 h and 24 h post infection.
These cytokines provide potential candidates for future experiments whereby we
hypothesise that modulating the expression of these cytokines will impact viral
replication in vitro. Of particular interest is the cytokine candidate SCL1A2 which
showed the greatest difference with a 71.9-fold increase 24 h post infection in HeLa
cells. SLC1A2 is known SLC35A1 solute carrier family 35 (CMP-sialic acid
transporter), member A1 and encodes a gene found in the membrane of the Golgi
apparatus, where it transports nucleotide sugars into the Golgi. An example of one
such sugar is CMP-sialic acid, which is imported into the Golgi by the protein
where it is glycosylated (http://www.ncbi.nlm.nih.gov/gene/10559). Some of these
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saliated glycans then act as receptors for viruses (Zhao, Chen et al. 2006). The
importance of SLC35A to the Golgi and the large upregulation seen in response to
infection with highly pathogenic avian influenza is of particular relevance when we
consider the inhibition of A/chicken/Vietnam/008/2004 H5N1 growth seen when
we disrupt Golgi function.
;:;8+*/8+):/549
Further investigation into the role these host cytokines such as SLC35A1 play in the
lifecycle of highly pathogenic avian influenza A/chicken/Vietnam/008/2004 H5N1
is required, in particular the interactions of COPA and the impact of silencing
COPA on the expression of SLC35A1 and the effects on
A/chicken/Vietnam/008/2004 H5N1 growth if we were to inhibit SLC35A1.
Modulating these candidates could be done by designing siRNAs against these
genes or by other methods such as chemical blockers. RNA interference is a
powerful method for gene knockdown, however for in vivo applications non siRNA
methods would be beneficial due to the expense and difficulty associated with
siRNA use in vivo which include, difficulty delivering the siRNAs, limited in vivo
stability, potential cellular toxicity and off target effects (Gao et al., 2011).
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